deferoxamine has been researched along with Disease Models, Animal in 242 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the pulmonary oxidative stress and possible protective effect of N-Acetylcysteine (NAC) and Desferoxamine (DFX)in a porcine model subjected to hemorrhagic shock." | 7.85 | N-Acetylcysteine and Desferoxamine Reduce Pulmonary Oxidative Stress Caused by Hemorrhagic Shock in a Porcine Model. ( Arkadopoulos, N; Karmaniolou, I; Mani, A; Mylonas, A; Nomikos, T; Orfanos, N; Pafiti, A; Papalois, A; Smyrniotis, V; Staikou, C; Theodoraki, K, 2017) |
| " This study is to examine the potential epilepsy control effect of deferoxamine (DFO), an iron chelator, on a ferric chloride-induced epilepsy rat model." | 7.85 | Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats. ( Cai, S; Chen, L; Jiang, S; Shi, Y; Wu, Z; Zhu, R; Zou, X, 2017) |
| "To investigate the effects of the iron chelatordeferoxamine (DFA) on inhibition formicroglia activation and protection of secondary nerve injury after intracerebral hemorrhage (ICH) in rats." | 7.83 | The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats. ( Jiang, L; Sun, YM; Wang, YT; Xue, MZ, 2016) |
| "In this study, we examined whether local deferoxamine (DFO) administration can promote angiogenesis and bone repair in steroid-induced osteonecrosis of the femoral head (ONFH)." | 7.81 | The effect of deferoxamine on angiogenesis and bone repair in steroid-induced osteonecrosis of rabbit femoral heads. ( Dang, X; Fan, L; Li, J; Wang, K; Yu, Z, 2015) |
| "Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 7.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
| "Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 7.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
| "We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 7.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
| "In this study, we examine the effects of deferoxamine on hemoglobin-induced brain swelling in a newly developed hippocampal model of intracerebral hemorrhage (ICH)." | 7.74 | Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage. ( He, Y; Hua, Y; Keep, RF; Song, S; Wang, J; Wu, J; Xi, G, 2008) |
| " The goal of this study was to clarify the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental SAH." | 7.74 | Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. ( Date, I; Hishikawa, T; Ogawa, T; Ono, S; Sugiu, K; Tokunaga, K, 2008) |
| "Preconditioning with hypoxia and hypoxia-mimetic compounds cobalt chloride (CoCl2) and desferrioxamine (DFX) protects against hypoxic-ischemic (HI) injury in neonatal rat brain." | 7.74 | Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desferrioxamine against hypoxic-ischemic injury in neonatal rats. ( Beart, PM; Callaway, JK; Jones, NM; Kardashyan, L; Lee, EM, 2008) |
| ") injection of a modified fibrin meshwork plus deferoxamine was tested in a rabbit model of acute hind-limb ischemia." | 7.72 | Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. ( Akhtar, M; Baibekov, I; Bajwa, T; Chekanov, VS; Hare, J; Karakozov, P; Nikolaychik, V; Tchekanov, G; Zargarian, M, 2003) |
| " The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits." | 7.72 | Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2004) |
| "This study investigated whether hepatocyte Ca2+ dysregulation after hemorrhagic shock and resuscitation could be modulated by the iron chelator hydroxyethyl starch-conjugated deferoxamine (HES-DFO)." | 7.70 | Starch-deferoxamine conjugate inhibits hepatocyte Ca2+ uptake during hemorrhagic shock and resuscitation. ( Pizanis, A; Rose, S; Silomon, M, 2000) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 7.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 7.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| "A single subcutaneous dose of 30 nmol of sodium selenite per gram of body weight in 13-day-old rats resulted in posterior subcapsular cataract (PSC) after 24 hr and bilateral nuclear cataracts at 72-96 hr." | 7.68 | Deferoxamine effect on selenite-induced cataract formation in rats. ( Bunce, GE; Hess, JL; Wang, Z, 1992) |
| "The present work deals with the effect of desferrioxamine (DF) on hexachlorobenzene (HCB)-induced porphyria in female rats with the purpose of further investigation of the role of iron in the development of this porphyria." | 7.67 | Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ( Aldonatti, CA; Billi, SC; San Martín de Viale, LC; Wainstock de Calmanovici, R, 1986) |
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 6.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| "Iron overload is commonly observed during the course of aplastic anemia (AA), which is believed to aggravate hematopoiesis, cause multiple organ dysfunction, lead to disease progression, and impair quality of life." | 5.48 | Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. ( Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y, 2018) |
| "Lactoferrin pretreatment of cells decreased LPS-mediated oxidative insults in a dose-dependent manner." | 5.36 | Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. ( Actor, JK; Bacsi, A; Boldogh, I; Kruzel, ML; Radak, Z; Saavedra-Molina, A, 2010) |
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 5.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| " We conclude that iron-chelation therapy with DFO at the above dosage results in a significant deterioration in cardiovascular function in septic swine." | 5.29 | Deferoxamine induces hypotension in experimental gram-negative septicemia. ( Bohnen, JM; Mullen, JB; Mustard, RA; Schouten, BD; Swanson, HT, 1994) |
| "4." | 5.29 | The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage. ( Aricioğlu, A; Aykol, S; Bilgihan, A; Cevik, C; Göksel, M; Türközkan, N, 1994) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 5.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| "Deferoxamine (DFO) to treat iron overload (IO) has been limited by toxicity issues and short circulation times and it would be desirable to prolong circulation to improve non-transferrin bound iron (NTBI) chelation." | 3.88 | Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. ( Chanana, S; Lin, TM; Liu, Z; Wang, Y; Xiong, MP, 2018) |
| "To investigate the pulmonary oxidative stress and possible protective effect of N-Acetylcysteine (NAC) and Desferoxamine (DFX)in a porcine model subjected to hemorrhagic shock." | 3.85 | N-Acetylcysteine and Desferoxamine Reduce Pulmonary Oxidative Stress Caused by Hemorrhagic Shock in a Porcine Model. ( Arkadopoulos, N; Karmaniolou, I; Mani, A; Mylonas, A; Nomikos, T; Orfanos, N; Pafiti, A; Papalois, A; Smyrniotis, V; Staikou, C; Theodoraki, K, 2017) |
| " This study is to examine the potential epilepsy control effect of deferoxamine (DFO), an iron chelator, on a ferric chloride-induced epilepsy rat model." | 3.85 | Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats. ( Cai, S; Chen, L; Jiang, S; Shi, Y; Wu, Z; Zhu, R; Zou, X, 2017) |
| "The aim of this study is to assess the efficacy of the combination of N-acetylcysteine (NAC) and deferoxamine (DFO) in the resuscitation from hemorrhagic shock in a porcine model of bleeding during hepatectomy." | 3.83 | The effects of antioxidants on a porcine model of liver hemorrhage. ( Arkadopoulos, NF; Dimas, C; Karmaniolou, II; Kondi-Pafiti, AI; Lolis, ED; Mylonas, AI; Orfanos, NF; Papalois, AE; Smyrniotis, VE; Stergiou, IP, 2016) |
| "These results indicate that membrane attack complex and erythrophagocytosis contribute to hematoma clearance after ICH, which can be altered by deferoxamine treatment." | 3.83 | Hematoma Changes During Clot Resolution After Experimental Intracerebral Hemorrhage. ( Cao, S; Chen, G; Hua, Y; Keep, RF; Xi, G; Zheng, M, 2016) |
| " Deferoxamine (DFX), a metal chelator, removes iron overload and protects against brain damage in intracranial hemorrhage." | 3.83 | Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages. ( He, XF; Lan, Y; Liang, FY; Liu, DX; Pei, Z; Wang, Q; Xu, GQ; Zeng, JS; Zhang, Q, 2016) |
| "To investigate the effects of the iron chelatordeferoxamine (DFA) on inhibition formicroglia activation and protection of secondary nerve injury after intracerebral hemorrhage (ICH) in rats." | 3.83 | The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats. ( Jiang, L; Sun, YM; Wang, YT; Xue, MZ, 2016) |
| "In this study, we examined whether local deferoxamine (DFO) administration can promote angiogenesis and bone repair in steroid-induced osteonecrosis of the femoral head (ONFH)." | 3.81 | The effect of deferoxamine on angiogenesis and bone repair in steroid-induced osteonecrosis of rabbit femoral heads. ( Dang, X; Fan, L; Li, J; Wang, K; Yu, Z, 2015) |
| "Asthma was induced in BALBc mice by ovalbumin, using aluminum hydroxide as an adjuvant." | 3.80 | Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma. ( Berenshtein, E; Bibi, H; Brod, V; Chevion, M; Elenberg, Y; Eliashar, R; Faingersh, A; Landesberg, A; Pesin, J; Vinokur, V; Waisman, D; Yadid, M, 2014) |
| "Sixty male mice were randomly divided into five groups: control, iron overload, low-dose Danshen (L-Danshen, 3g/kg/day), high-dose Danshen (H-Danshen, 6g/kg/day) and deferoxamine (DFO) groups (n=12 per group)." | 3.79 | Mechanism of protective effects of Danshen against iron overload-induced injury in mice. ( Chu, L; Gao, Y; Guan, P; Ma, J; Ma, Z; Wang, J; Wang, N; Zhang, J; Zhang, X; Zhang, Y, 2013) |
| "Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 3.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
| "Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 3.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
| "We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 3.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
| "In this study, we examine the effects of deferoxamine on hemoglobin-induced brain swelling in a newly developed hippocampal model of intracerebral hemorrhage (ICH)." | 3.74 | Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage. ( He, Y; Hua, Y; Keep, RF; Song, S; Wang, J; Wu, J; Xi, G, 2008) |
| " The goal of this study was to clarify the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental SAH." | 3.74 | Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. ( Date, I; Hishikawa, T; Ogawa, T; Ono, S; Sugiu, K; Tokunaga, K, 2008) |
| "Preconditioning with hypoxia and hypoxia-mimetic compounds cobalt chloride (CoCl2) and desferrioxamine (DFX) protects against hypoxic-ischemic (HI) injury in neonatal rat brain." | 3.74 | Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desferrioxamine against hypoxic-ischemic injury in neonatal rats. ( Beart, PM; Callaway, JK; Jones, NM; Kardashyan, L; Lee, EM, 2008) |
| "We investigated the time course of electrocardiographic (ECG) changes in the Mongolian gerbil model of iron overload and the effects of the iron chelator deferoxamine (DFO) on these changes." | 3.72 | Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| ") injection of a modified fibrin meshwork plus deferoxamine was tested in a rabbit model of acute hind-limb ischemia." | 3.72 | Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. ( Akhtar, M; Baibekov, I; Bajwa, T; Chekanov, VS; Hare, J; Karakozov, P; Nikolaychik, V; Tchekanov, G; Zargarian, M, 2003) |
| " The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits." | 3.72 | Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2004) |
| " Two studies were conducted to assess the efficacy of the complexes of desferrioxamine with zinc or gallium to prevent this aspect of reperfusion injury." | 3.71 | The push-and-pull mechanism to scavenge redox-active transition metals: a novel concept in myocardial protection. ( Berenshtein, E; Chevion, M; Haverich, A; Karck, M; Sturm, C; Tanaka, S, 2001) |
| " The effects of an HO inhibitor, tin-protoporphyrin (SnPP), and the iron chelator deferoxamine, on hemoglobin-induced brain edema were also examined." | 3.71 | Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. ( Hoff, JT; Hua, Y; Huang, FP; Keep, RF; Nemoianu, A; Xi, G, 2002) |
| "Although the beneficial effects of deferoxamine (DFO) on iron-associated morbidity and mortality are well documented, the role of deferiprone (L1) in the management of transfusional iron overload is controversial." | 3.71 | The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. ( Hershko, C; Huerta, M; Konijn, AM; Link, G; Reinus, C; Rosenmann, E, 2002) |
| "This study investigated whether hepatocyte Ca2+ dysregulation after hemorrhagic shock and resuscitation could be modulated by the iron chelator hydroxyethyl starch-conjugated deferoxamine (HES-DFO)." | 3.70 | Starch-deferoxamine conjugate inhibits hepatocyte Ca2+ uptake during hemorrhagic shock and resuscitation. ( Pizanis, A; Rose, S; Silomon, M, 2000) |
| " Further, there is lack of agreement about the benefits of deferoxamine (Dfx) in the treatment of anemia and oxidative stress during inflammation and chronic diseases." | 3.69 | Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine. ( Mitjavila, MT; Muntané, J; Puig-Parellada, P, 1995) |
| "A controversial therapy in the management of acute iron poisoning is the oral administration of deferoxamine which purportedly complexes unabsorbed iron, exerts protection at the cellular level, and/or enhances the renal elimination of ingested iron." | 3.69 | Iron complexation with oral deferoxamine in a swine model. ( Dean, BS; Griffith, GR; Hines, RH; Krenzelok, EP; Oehme, FW, 1996) |
| " In a separate in vivo study, the iron chelator, deferoxamine, prevented the increase in the bleomycin-detectable iron in glomeruli and provided complete protection against proteinuria." | 3.69 | Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome. ( Baliga, R; Shah, SV; Ueda, N, 1996) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 3.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 3.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| "A single subcutaneous dose of 30 nmol of sodium selenite per gram of body weight in 13-day-old rats resulted in posterior subcapsular cataract (PSC) after 24 hr and bilateral nuclear cataracts at 72-96 hr." | 3.68 | Deferoxamine effect on selenite-induced cataract formation in rats. ( Bunce, GE; Hess, JL; Wang, Z, 1992) |
| "An ovine model of maternal iron poisoning in pregnancy was used to examine the placental transport of deferoxamine and ferrioxamine and to follow maternal and fetal serum iron concentrations when maternal serum iron levels exceeded total iron-binding capacity." | 3.68 | An ovine model of maternal iron poisoning in pregnancy. ( Bond, GR; Curry, SC; Raschke, R; Tellez, D; Wiggins, D, 1990) |
| " Treatment of experimental uveitis in Lewis rats with an iron chelator, deferoxamine mesylate, resulted in marked reduction in choroidal inflammation and suppression of retinal damage." | 3.67 | Effect of iron chelation on severity of ocular inflammation in an animal model. ( Fernandez, MA; Marak, GE; Rao, NA; Romero, JL; Sevanian, A, 1986) |
| "The present work deals with the effect of desferrioxamine (DF) on hexachlorobenzene (HCB)-induced porphyria in female rats with the purpose of further investigation of the role of iron in the development of this porphyria." | 3.67 | Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ( Aldonatti, CA; Billi, SC; San Martín de Viale, LC; Wainstock de Calmanovici, R, 1986) |
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 2.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| "Hemochromatosis is a syndrome which, when fully expressed, is manifested by melanoderma , diabetes mellitus, and liver cirrhosis, with iron overload involving parenchymal and reticuloendothelial cells in many organ systems." | 2.36 | Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. ( Kellermeyer, RW; McLaren, GD; Muir, WA, 1983) |
| "However, its role in pulmonary fibrosis, a fatal lung disease with unknown etiology, is largely unknown." | 1.62 | Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis. ( Cheng, H; Feng, D; Gao, L; Li, C; Li, X; Liu, W; Luo, Z; Tang, S; Wu, X; Yue, S, 2021) |
| "Deferoxamine (DFX) has been reported to have neuroprotective effect." | 1.56 | HIF-1α and VEGF Are Involved in Deferoxamine-Ameliorated Traumatic Brain Injury. ( Chen, S; Gong, Q; Jing, Y; Wang, K; Xu, C; Zhao, J, 2020) |
| "The reversal of catalepsy behaviour represents the protective effect of above combination on dopamine neurons in striatum from 6-OHDA toxicity." | 1.51 | Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels. ( Antony, J; Choephel, T; Jeyarani, V; Jose, A; Kannan, E; Karolina Sahadevan, S; Manisha, C; Mannan Thodukayil, N; Thomas, P, 2019) |
| "Deferoxamine treatment of the iron-loaded zebrafish larvae showed a significant decrease in total iron concentration." | 1.48 | Zebrafish larvae as a model to demonstrate secondary iron overload. ( Baji, MH; Mustafa, I; Nasrallah, GK; Shraim, AM; Younes, NN, 2018) |
| "Posthemorrhagic hydrocephalus (PHH) is a common complication of GMH." | 1.48 | Targeting Germinal Matrix Hemorrhage-Induced Overexpression of Sodium-Coupled Bicarbonate Exchanger Reduces Posthemorrhagic Hydrocephalus Formation in Neonatal Rats. ( Ding, Y; Krafft, P; Li, Q; Wan, W; Wu, G; Yan, F; Zhan, Q; Zhang, JH; Zhang, Y, 2018) |
| "Iron overload is commonly observed during the course of aplastic anemia (AA), which is believed to aggravate hematopoiesis, cause multiple organ dysfunction, lead to disease progression, and impair quality of life." | 1.48 | Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. ( Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y, 2018) |
| "Deferoxamine was delivered topically for 10 days following radiation." | 1.48 | Topical Deferoxamine Alleviates Skin Injury and Normalizes Atomic Force Microscopy Patterns Following Radiation in a Murine Breast Reconstruction Model. ( Banaszak Holl, MM; Buchman, SR; Donneys, A; Ettinger, RE; Gurtner, GC; Lynn, JV; Nelson, NS; Polyatskaya, Y; Snider, AE; Urlaub, KM, 2018) |
| "Deferoxamine treatment attenuated ICH-induced CD163 upregulation and significantly reduced both brain CD163 and hemoglobin levels at day 3." | 1.46 | CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage. ( Cao, S; Hua, Y; Huang, Y; Keep, RF; Liu, R; Xi, G, 2017) |
| "Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative disease and insult including Alzheimer's disease, Parkinson's disease, stroke, and subarachnoid hemorrhage." | 1.46 | Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease. ( Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Haase, LR; Hamel, KA; Hanson, LR; Kaczmarczek, KD; Knutzen, KE; Raney, EB; Stroebel, BM; Verden, DR, 2017) |
| "Post-hemorrhagic chronic hydrocephalus (PHCH) is a common complication after intraventricular hemorrhage (IVH)." | 1.42 | Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition. ( Feng, H; Gong, G; Hu, R; Hu, S; Li, F; Meng, H; Yuan, Y, 2015) |
| "Deferoxamine is a U." | 1.42 | Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model. ( Best, R; Das, A; Lin, KY; Mericli, AF; Rodeheaver, G; Rodeheaver, P, 2015) |
| "Paradoxal sleep deprivation (PSD) in mice has been considered a good animal model of mania because it induces similar manic-like behavior, as well as producing the neurochemical alterations which have been observed in bipolar patients." | 1.42 | The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania. ( Amboni, RT; Arent, CO; Bianchini, G; Dal-Pont, GC; Lopes-Borges, J; Quevedo, J; Resende, WR; Steckert, AV; Valvassori, SS, 2015) |
| "Lesion-induced scarring is a major impediment for regeneration of injured axons in the central nervous system (CNS)." | 1.42 | Pharmacological Suppression of CNS Scarring by Deferoxamine Reduces Lesion Volume and Increases Regeneration in an In Vitro Model for Astroglial-Fibrotic Scarring and in Rat Spinal Cord Injury In Vivo. ( Brazda, N; Estrada, V; Faissner, A; König, B; Krafft, S; Müller, HW; Vogelaar, CF; Ziegler, B, 2015) |
| "The role of CD47 in intracerebral hemorrhage (ICH) has not been investigated and the current study examined brain CD47 expression in a pig ICH model." | 1.40 | Brain CD47 expression in a swine model of intracerebral hemorrhage. ( Hua, Y; Keep, RF; Xi, G; Xie, Q; Zhou, X, 2014) |
| "Rat models with 6-OHDA-induced Parkinson's disease were treated with curcumin, DFO, or both and the effect of different treatments on dopamine level was examined." | 1.40 | Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease. ( Cui, X; Jiang, F; Li, Z; Liu, J; Lv, H; Niu, Y; Wang, L; Wang, W; Yu, S; Yuan, J; Zhang, H, 2014) |
| "The pathogenesis of posthemorrhagic hydrocephalus is not fully understood." | 1.40 | Role of hemoglobin and iron in hydrocephalus after neonatal intraventricular hemorrhage. ( Bazzi, AA; Garton, HJ; Garton, T; Keep, RF; Kilaru, H; Maher, CO; Muraszko, KM; Strahle, JM; Xi, G, 2014) |
| "Pyrophosphate was shown to participate in iron transfer from transferrin to ferritin." | 1.40 | Pyrophosphate-mediated iron acquisition from transferrin in Neisseria meningitidis does not require TonB activity. ( Biville, F; Brézillon, C; Giorgini, D; Taha, MK, 2014) |
| " Our data suggest that chronic administration of intranasal deferoxamine may be a valid approach to limiting the mishandling of α-synuclein in the central nervous system observed in Parkinson's disease and slowing disease progression." | 1.39 | Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. ( Andersen, KJ; Febbraro, F; Romero-Ramos, M; Sanchez-Guajardo, V; Tentillier, N, 2013) |
| " Our results reveal that our novel formulation lowered the dosage requirements by 50%-75%, allowed for less frequent and shorter treatment durations, eliminating the need for a pump and the standard multi-night administration of DFO." | 1.39 | Sickle cell anemia: the impact of discovery, politics, and business. ( Conley, E; Doye, AA; Gwathmey, JK; Xie, LH, 2013) |
| "Acute necrotizing pancreatitis was induced by retrograde intraductal injection of sodium taurocholate in rats." | 1.39 | Heme oxygenase 1-generated carbon monoxide and biliverdin attenuate the course of experimental necrotizing pancreatitis. ( Berberat, PO; Bergmann, F; Ceyhan, GO; Fischer, L; Friess, H; Giese, N; Künzli, BM; Mitkus, T; Nuhn, P, 2013) |
| " Because the neurotoxic mechanisms of MSUD are poorly understood, this study aimed to evaluate the effects of chronic administration of a BCAA pool (leucine, isoleucine and valine)." | 1.39 | Chronic administration of branched-chain amino acids impairs spatial memory and increases brain-derived neurotrophic factor in a rat model. ( Bogo, MR; Comim, CM; Ferreira, GC; Gelain, DP; Moreira, JC; Oliveira, GM; Pasquali, MA; Quevedo, J; Scaini, G; Schuck, PF; Streck, EL, 2013) |
| "Ischemia/reperfusion injury is a leading cause of acute renal failure triggering an inflammatory response associated with infiltrating macrophages, which determine disease outcome." | 1.38 | Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. ( Hotter, G; Hughes, J; Jung, M; Kluth, DC; Pérez-Ladaga, A; Sola, A; Viñas, JL; Vinuesa, E, 2012) |
| " Here, we investigated whether acute and chronic administration of a BCAA pool causes impairment of acquisition and retention of avoidance memory in young rats." | 1.38 | Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease. ( Comim, CM; Dominguini, D; Ferreira, GC; Jeremias, IC; Mina, F; Morais, MO; Pescador, B; Quevedo, J; Scaini, G; Schuck, PF; Streck, EL; Teodorak, BP, 2012) |
| "Spinal cord ischemia was induced in Sprague-Dawley rats by infrarenal aortic occlusion for 30 min followed by 72 h of reperfusion." | 1.37 | Additive effect of tetramethylpyrazine and deferoxamine in the treatment of spinal cord injury caused by aortic cross-clamping in rats. ( Jiang, DM; Liang, Y; Yang, QH; Yu, XD, 2011) |
| "Deferoxamine treatment reduced the perihematomal reddish zone, and the number of Perls' (p<0." | 1.37 | Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage. ( Gu, Y; He, Y; Hu, H; Hua, Y; Keep, RF; Wang, L; Xi, G, 2011) |
| "Lactoferrin pretreatment of cells decreased LPS-mediated oxidative insults in a dose-dependent manner." | 1.36 | Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. ( Actor, JK; Bacsi, A; Boldogh, I; Kruzel, ML; Radak, Z; Saavedra-Molina, A, 2010) |
| "Deferoxamine treated control myocytes responded similarly." | 1.36 | Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. ( Scholz, PM; Tan, T; Weiss, HR, 2010) |
| "Deferoxamine-treated animals had reduced total bilirubin, gamma-glutamyl transferase and ammonia levels as well as hepatocyte necrosis and oxidative injury." | 1.36 | Iron chelation for amelioration of liver ischemia-reperfusion injury. ( Arkadopoulos, N; Economou, E; Kalimeris, K; Kostopanagiotou, G; Kouskouni, E; Nastos, C; Pafiti, A; Smyrniotis, V; Theodoraki, K, 2010) |
| " In the present study, the effects of benznidazole (BZ) therapy in combination with the iron chelator desferrioxamine (DFO) on the development of infection in mice inoculated with Trypanosoma cruzi Y strain have been investigated." | 1.35 | Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. ( Arantes, JM; Bahia, MT; Carneiro, CM; de Abreu Vieira, PM; de Lana, M; Francisco, AF; Martins, HR; Pedrosa, ML; Silva, M; Tafuri, WL; Veloso, VM, 2008) |
| "Brain edema induced by intracerebral hemorrhage (ICH) is a serious problem in the treatment of ICH." | 1.35 | Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats. ( Bao, X; Hu, S; Huang, F; Wu, G, 2008) |
| "DFO induced tolerance against focal cerebral ischemia in rats, and exerted protective effect on OGD cultured cortical neurons." | 1.35 | Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. ( Ding, SJ; Guo, W; Li, YX; Xiao, L; Zhan, Q, 2008) |
| "Ulcerative colitis is a chronic inflammatory disease of the gastrointestinal tract." | 1.34 | Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. ( Bardini, KC; Benetton, CA; Cardoso, VH; Dal-Pizzol, F; Damiani, CR; Di Giunta, G; Pinho, RA; Stoffel, C; Streck, EL, 2007) |
| "Treatment with deferoxamine (DFO) is protective against focal ischemia with global hypoxia when given as a preconditioning stimulus in neonatal rodents." | 1.33 | Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. ( Chang, YS; Ferriero, DM; Mu, D; Vexler, ZS, 2005) |
| "Glycerol treatment resulted in marked renal oxidative stress and deranged renal functions which significantly improved by trimetazidine and deferoxamine treatments." | 1.32 | Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. ( Chander, V; Chopra, K; Singh, D, 2003) |
| "Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulphonic acid." | 1.32 | Effects of iron deprivation or chelation on DNA damage in experimental colitis. ( Angriman, I; Barollo, M; Cardin, R; D'Incà, R; Fries, W; Medici, V; Scarpa, M; Sturniolo, GC, 2004) |
| "Deferoxamine treatment prevented these effects, while the usefulness of L-arginine remained doubtful." | 1.31 | Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats. ( Balogh, N; Gaál, T; Krausz, F; Lévai, P; Ribiczeyné, PS; Vajdovich, P, 2002) |
| "Our findings suggest that DFO administration may be safe and useful for ameliorating cisplatin-induced nephrotoxicity." | 1.31 | Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity. ( Dokucu, AI; Ece, A; Ozdemir, E; Oztürk, H; Uzunlar, AK; Yaldiz, M, 2002) |
| " Three doses of 200, 300 and 400 mg/kg DFO were used either alone or in combination with pyrimethamine." | 1.30 | Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice. ( Mahmoud, MS, 1999) |
| "Hemoglobin (Hb) is a toxic molecule responsible for the extreme lethality associated with experimental Escherichia coli peritonitis, but the mechanism has yet to be elucidated." | 1.30 | Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species. ( Han, JA; Kim, KM; Kim, SS; Kim, YM; Lea, HZ; Yoo, YM, 1999) |
| " Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria." | 1.29 | Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. ( Chin, K; Clarkson, AB; Grady, RW; Merali, S; Weissberger, L, 1995) |
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 1.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| " We conclude that iron-chelation therapy with DFO at the above dosage results in a significant deterioration in cardiovascular function in septic swine." | 1.29 | Deferoxamine induces hypotension in experimental gram-negative septicemia. ( Bohnen, JM; Mullen, JB; Mustard, RA; Schouten, BD; Swanson, HT, 1994) |
| "4." | 1.29 | The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage. ( Aricioğlu, A; Aykol, S; Bilgihan, A; Cevik, C; Göksel, M; Türközkan, N, 1994) |
| "Pretreatment with deferoxamine resulted in a significant decrease in lung leak as compared to animals pretreated with vehicle prior to I/R (DES-I/R = 0." | 1.29 | Desferal attenuates TNF release following hepatic ischemia/reperfusion. ( Campbell, DA; Colletti, LM; Remick, DG, 1994) |
| "In dogs, gastric dilatation-volvulus (GDV) is characterized by cardiogenic shock, with resulting hypoperfusion." | 1.28 | Treatment of reperfusion injury in dogs with experimentally induced gastric dilatation-volvulus. ( Arkin, TE; Badylak, SF; Hiles, MC; Lantz, GC, 1992) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 1.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| "Frostbite is characterized by acute tissue injury induced by freezing and thawing." | 1.28 | Evidence for an early free radical-mediated reperfusion injury in frostbite. ( Bulkley, GB; Im, MJ; Jesudass, R; Manson, PN; Marzella, L; Narayan, KK, 1991) |
| "Deferoxamine-treated animals had an inulin clearance of 0." | 1.27 | Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. ( Paller, MS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (7.44) | 18.7374 |
| 1990's | 44 (18.18) | 18.2507 |
| 2000's | 55 (22.73) | 29.6817 |
| 2010's | 113 (46.69) | 24.3611 |
| 2020's | 12 (4.96) | 2.80 |
| Authors | Studies |
|---|---|
| Le Douaron, G | 1 |
| Ferrié, L | 1 |
| Sepulveda-Diaz, JE | 1 |
| Amar, M | 1 |
| Harfouche, A | 1 |
| Séon-Méniel, B | 1 |
| Raisman-Vozari, R | 1 |
| Michel, PP | 1 |
| Figadère, B | 1 |
| Jin, T | 1 |
| He, Q | 1 |
| Cheng, C | 1 |
| Li, H | 1 |
| Liang, L | 1 |
| Zhang, G | 1 |
| Su, C | 1 |
| Xiao, Y | 1 |
| Bradley, J | 1 |
| Peberdy, MA | 1 |
| Ornato, JP | 1 |
| Tang, W | 1 |
| van Swelm, RPL | 1 |
| Beurskens, S | 1 |
| Dijkman, H | 1 |
| Wiegerinck, ETG | 1 |
| Roelofs, R | 1 |
| Thévenod, F | 1 |
| van der Vlag, J | 1 |
| Wetzels, JFM | 1 |
| Swinkels, DW | 1 |
| Smeets, B | 1 |
| Kwan, P | 1 |
| Ho, A | 1 |
| Baum, L | 1 |
| Wang, K | 2 |
| Jing, Y | 1 |
| Xu, C | 1 |
| Zhao, J | 1 |
| Gong, Q | 1 |
| Chen, S | 1 |
| Yamada, N | 1 |
| Karasawa, T | 1 |
| Kimura, H | 1 |
| Watanabe, S | 1 |
| Komada, T | 1 |
| Kamata, R | 1 |
| Sampilvanjil, A | 1 |
| Ito, J | 1 |
| Nakagawa, K | 1 |
| Kuwata, H | 1 |
| Hara, S | 1 |
| Mizuta, K | 1 |
| Sakuma, Y | 1 |
| Sata, N | 1 |
| Takahashi, M | 1 |
| Pasupneti, S | 1 |
| Tian, W | 1 |
| Tu, AB | 1 |
| Dahms, P | 1 |
| Granucci, E | 1 |
| Gandjeva, A | 1 |
| Xiang, M | 1 |
| Butcher, EC | 1 |
| Semenza, GL | 1 |
| Tuder, RM | 1 |
| Jiang, X | 1 |
| Nicolls, MR | 1 |
| Yang, RZ | 1 |
| Xu, WN | 1 |
| Zheng, HL | 1 |
| Zheng, XF | 1 |
| Li, B | 1 |
| Jiang, LS | 1 |
| Jiang, SD | 1 |
| Farr, AC | 1 |
| Xiong, MP | 2 |
| Kim, KM | 2 |
| Cho, SS | 1 |
| Ki, SH | 1 |
| Tu, H | 1 |
| Zhou, YJ | 1 |
| Tang, LJ | 1 |
| Xiong, XM | 1 |
| Zhang, XJ | 1 |
| Ali Sheikh, MS | 1 |
| Zhang, JJ | 1 |
| Luo, XJ | 1 |
| Yuan, C | 1 |
| Peng, J | 1 |
| Cheng, H | 1 |
| Feng, D | 1 |
| Li, X | 2 |
| Gao, L | 1 |
| Tang, S | 1 |
| Liu, W | 3 |
| Wu, X | 1 |
| Yue, S | 1 |
| Li, C | 1 |
| Luo, Z | 1 |
| Gasparotto, J | 1 |
| Senger, MR | 1 |
| Telles de Sá Moreira, E | 1 |
| Brum, PO | 1 |
| Carazza Kessler, FG | 1 |
| Peixoto, DO | 1 |
| Panzenhagen, AC | 1 |
| Ong, LK | 1 |
| Campos Soares, M | 1 |
| Reis, PA | 1 |
| Schirato, GV | 1 |
| Góes Valente, WC | 1 |
| Araújo Montoya, BO | 1 |
| Silva, FP | 1 |
| Fonseca Moreira, JC | 2 |
| Dal-Pizzol, F | 6 |
| Castro-Faria-Neto, HC | 1 |
| Gelain, DP | 2 |
| Liu, R | 1 |
| Cao, S | 2 |
| Hua, Y | 16 |
| Keep, RF | 16 |
| Huang, Y | 2 |
| Xi, G | 17 |
| Gotsbacher, MP | 1 |
| Telfer, TJ | 1 |
| Witting, PK | 1 |
| Double, KL | 1 |
| Finkelstein, DI | 1 |
| Codd, R | 1 |
| Fine, JM | 1 |
| Forsberg, AC | 1 |
| Stroebel, BM | 1 |
| Faltesek, KA | 1 |
| Verden, DR | 1 |
| Hamel, KA | 1 |
| Raney, EB | 1 |
| Crow, JM | 1 |
| Haase, LR | 1 |
| Knutzen, KE | 1 |
| Kaczmarczek, KD | 1 |
| Frey, WH | 1 |
| Hanson, LR | 1 |
| Wang, L | 3 |
| Jia, P | 1 |
| Shan, Y | 1 |
| Hao, Y | 1 |
| Wang, X | 1 |
| Jiang, Y | 1 |
| Yuan, Y | 2 |
| Du, Q | 1 |
| Zhang, H | 2 |
| Yang, F | 1 |
| Zhang, W | 1 |
| Sheng, M | 1 |
| Xu, Y | 1 |
| Zhang, Y | 4 |
| He, ML | 1 |
| Ishida, Y | 1 |
| Okamoto, Y | 1 |
| Matsuoka, Y | 1 |
| Tada, A | 1 |
| Janprasit, J | 1 |
| Yamato, M | 1 |
| Morales, NP | 2 |
| Yamada, KI | 1 |
| Wang, Y | 2 |
| Liu, Z | 1 |
| Lin, TM | 1 |
| Chanana, S | 1 |
| Nasrallah, GK | 1 |
| Younes, NN | 1 |
| Baji, MH | 1 |
| Shraim, AM | 1 |
| Mustafa, I | 1 |
| Li, Q | 1 |
| Ding, Y | 1 |
| Krafft, P | 1 |
| Wan, W | 1 |
| Yan, F | 1 |
| Wu, G | 2 |
| Zhan, Q | 2 |
| Zhang, JH | 2 |
| Wu, D | 1 |
| Wen, X | 1 |
| Hu, H | 2 |
| Ye, B | 1 |
| Zhou, Y | 1 |
| Savage, KA | 1 |
| Parquet, MC | 1 |
| Allan, DS | 1 |
| Davidson, RJ | 1 |
| Holbein, BE | 1 |
| Lilly, EA | 1 |
| Fidel, PL | 1 |
| Farzan, R | 1 |
| Moeinian, M | 1 |
| Abdollahi, A | 1 |
| Jahangard-Rafsanjani, Z | 1 |
| Alipour, A | 1 |
| Ebrahimi, M | 1 |
| Khorasani, G | 1 |
| Snider, AE | 1 |
| Lynn, JV | 1 |
| Urlaub, KM | 1 |
| Donneys, A | 4 |
| Polyatskaya, Y | 1 |
| Nelson, NS | 2 |
| Ettinger, RE | 1 |
| Gurtner, GC | 3 |
| Banaszak Holl, MM | 1 |
| Buchman, SR | 4 |
| Zhu, W | 1 |
| Ye, Y | 1 |
| Bonham, CA | 1 |
| Rodrigues, M | 1 |
| Galvez, M | 1 |
| Trotsyuk, A | 1 |
| Stern-Buchbinder, Z | 1 |
| Inayathullah, M | 1 |
| Rajadas, J | 1 |
| Abdelgelil, NH | 1 |
| Abdellatif, MZM | 1 |
| Abdel-Hafeez, EH | 1 |
| Belal, US | 1 |
| Mohamed, RM | 1 |
| Abdel-Razik, AH | 1 |
| Hassanin, KMA | 1 |
| Abdel-Wahab, A | 1 |
| Dassoulas, KR | 1 |
| Mericli, AF | 2 |
| Wang, JS | 1 |
| Lei, SS | 1 |
| Kim, T | 1 |
| Cottler, PS | 1 |
| Lin, KY | 2 |
| Qin, Y | 1 |
| Li, G | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Gu, J | 2 |
| Gao, F | 1 |
| Mannan Thodukayil, N | 1 |
| Antony, J | 1 |
| Thomas, P | 1 |
| Jeyarani, V | 1 |
| Choephel, T | 1 |
| Manisha, C | 1 |
| Jose, A | 1 |
| Karolina Sahadevan, S | 1 |
| Kannan, E | 1 |
| Zhu, Q | 1 |
| Gong, Y | 1 |
| Guo, T | 1 |
| Deng, J | 1 |
| Ji, J | 1 |
| Wang, B | 1 |
| Hao, S | 1 |
| Dong, M | 1 |
| Febbraro, F | 1 |
| Andersen, KJ | 1 |
| Sanchez-Guajardo, V | 1 |
| Tentillier, N | 1 |
| Romero-Ramos, M | 1 |
| Ahsan, S | 1 |
| Perosky, JE | 1 |
| Deshpande, SS | 3 |
| Tchanque-Fossuo, CN | 2 |
| Levi, B | 1 |
| Kozloff, KM | 1 |
| Kajbafzadeh, AM | 1 |
| Sabetkish, N | 1 |
| Sabetkish, S | 1 |
| Javan-Farazmand, N | 1 |
| Harsini, S | 1 |
| Tavangar, SM | 1 |
| Saljooghi, AS | 1 |
| Babaie, M | 1 |
| Mendi, FD | 1 |
| Zahmati, M | 1 |
| Saljooghi, ZS | 1 |
| Gelosa, P | 1 |
| Pignieri, A | 1 |
| Gianazza, E | 1 |
| Criniti, S | 1 |
| Guerrini, U | 1 |
| Cappellini, MD | 1 |
| Banfi, C | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Chen, J | 2 |
| Marks, E | 1 |
| Lai, B | 1 |
| Zhang, Z | 1 |
| Duce, JA | 1 |
| Lam, LQ | 1 |
| Volitakis, I | 1 |
| Bush, AI | 1 |
| Hersch, S | 1 |
| Fox, JH | 1 |
| Hatakeyama, T | 3 |
| Okauchi, M | 4 |
| Xie, LH | 1 |
| Doye, AA | 1 |
| Conley, E | 1 |
| Gwathmey, JK | 1 |
| Imran ul-haq, M | 1 |
| Hamilton, JL | 1 |
| Lai, BF | 1 |
| Shenoi, RA | 1 |
| Horte, S | 1 |
| Constantinescu, I | 1 |
| Leitch, HA | 1 |
| Kizhakkedathu, JN | 1 |
| Chen, B | 1 |
| Yan, YL | 1 |
| Liu, C | 1 |
| Bo, L | 1 |
| Li, GF | 1 |
| Wang, H | 1 |
| Xu, YJ | 1 |
| Ayvaz, S | 1 |
| Inan, M | 1 |
| Aksu, B | 1 |
| Karaca, T | 1 |
| Cemek, M | 1 |
| Ayaz, A | 1 |
| Basaran, UN | 1 |
| Pul, M | 1 |
| Farberg, AS | 1 |
| Sarhaddi, D | 1 |
| Niu, X | 1 |
| Huang, WH | 1 |
| De Boer, B | 1 |
| Delriviere, L | 1 |
| Mou, LJ | 1 |
| Jeffrey, GP | 1 |
| Page, EE | 1 |
| Felice, PA | 1 |
| Spiegel, JP | 1 |
| Yatmark, P | 1 |
| Chaisri, U | 1 |
| Wichaiyo, S | 1 |
| Hemstapat, W | 1 |
| Srichairatanakool, S | 2 |
| Svasti, S | 1 |
| Fucharoen, S | 4 |
| Zhou, X | 1 |
| Xie, Q | 1 |
| Klebe, D | 1 |
| Krafft, PR | 1 |
| Hoffmann, C | 1 |
| Lekic, T | 1 |
| Flores, JJ | 1 |
| Rolland, W | 1 |
| Lv, H | 1 |
| Liu, J | 3 |
| Yu, S | 1 |
| Li, Z | 1 |
| Jiang, F | 1 |
| Niu, Y | 1 |
| Yuan, J | 1 |
| Cui, X | 1 |
| Wang, W | 1 |
| Bibi, H | 1 |
| Vinokur, V | 1 |
| Waisman, D | 1 |
| Elenberg, Y | 1 |
| Landesberg, A | 1 |
| Faingersh, A | 1 |
| Yadid, M | 1 |
| Brod, V | 1 |
| Pesin, J | 1 |
| Berenshtein, E | 4 |
| Eliashar, R | 1 |
| Chevion, M | 4 |
| Strahle, JM | 1 |
| Garton, T | 1 |
| Bazzi, AA | 1 |
| Kilaru, H | 1 |
| Garton, HJ | 1 |
| Maher, CO | 1 |
| Muraszko, KM | 1 |
| Meng, H | 2 |
| Li, F | 2 |
| Hu, R | 2 |
| Gong, G | 1 |
| Hu, S | 2 |
| Feng, H | 2 |
| Arifin, AJ | 1 |
| Hannauer, M | 1 |
| Welch, I | 1 |
| Heinrichs, DE | 1 |
| Biville, F | 1 |
| Brézillon, C | 1 |
| Giorgini, D | 1 |
| Taha, MK | 1 |
| Li, J | 1 |
| Fan, L | 1 |
| Yu, Z | 1 |
| Dang, X | 1 |
| Seo, JW | 1 |
| Mahakian, LM | 1 |
| Tam, S | 1 |
| Qin, S | 1 |
| Ingham, ES | 1 |
| Meares, CF | 1 |
| Ferrara, KW | 1 |
| Das, A | 1 |
| Best, R | 1 |
| Rodeheaver, P | 1 |
| Rodeheaver, G | 1 |
| Zhang, XY | 1 |
| Cao, JB | 1 |
| Zhang, LM | 1 |
| Li, YF | 1 |
| Mi, WD | 1 |
| Ni, W | 1 |
| Gu, Y | 3 |
| Gammella, E | 1 |
| Recalcati, S | 1 |
| Rybinska, I | 1 |
| Buratti, P | 1 |
| Cairo, G | 1 |
| Arent, CO | 1 |
| Valvassori, SS | 2 |
| Steckert, AV | 1 |
| Resende, WR | 1 |
| Dal-Pont, GC | 1 |
| Lopes-Borges, J | 1 |
| Amboni, RT | 1 |
| Bianchini, G | 1 |
| Quevedo, J | 4 |
| Cui, HJ | 1 |
| He, HY | 1 |
| Yang, AL | 1 |
| Zhou, HJ | 1 |
| Wang, C | 1 |
| Luo, JK | 1 |
| Lin, Y | 1 |
| Tang, T | 2 |
| Vogelaar, CF | 1 |
| König, B | 1 |
| Krafft, S | 1 |
| Estrada, V | 1 |
| Brazda, N | 1 |
| Ziegler, B | 1 |
| Faissner, A | 1 |
| Müller, HW | 1 |
| Smalley, JL | 1 |
| Breda, C | 1 |
| Mason, RP | 2 |
| Kooner, G | 1 |
| Luthi-Carter, R | 1 |
| Gant, TW | 1 |
| Giorgini, F | 1 |
| Tavaré, R | 1 |
| Escuin-Ordinas, H | 1 |
| Mok, S | 1 |
| McCracken, MN | 1 |
| Zettlitz, KA | 1 |
| Salazar, FB | 1 |
| Witte, ON | 1 |
| Ribas, A | 1 |
| Wu, AM | 1 |
| Houghton, JL | 1 |
| Zeglis, BM | 1 |
| Abdel-Atti, D | 1 |
| Aggeler, R | 1 |
| Sawada, R | 1 |
| Agnew, BJ | 1 |
| Scholz, WW | 1 |
| Lewis, JS | 1 |
| Cheng, F | 1 |
| Bourseau-Guilmain, E | 1 |
| Belting, M | 1 |
| Fransson, LÅ | 1 |
| Mani, K | 1 |
| Elenbaas, JS | 1 |
| Maitra, D | 1 |
| Liu, Y | 1 |
| Lentz, SI | 1 |
| Nelson, B | 1 |
| Hoenerhoff, MJ | 1 |
| Shavit, JA | 1 |
| Omary, MB | 1 |
| Orfanos, NF | 1 |
| Mylonas, AI | 1 |
| Karmaniolou, II | 1 |
| Stergiou, IP | 1 |
| Lolis, ED | 1 |
| Dimas, C | 1 |
| Papalois, AE | 1 |
| Kondi-Pafiti, AI | 1 |
| Smyrniotis, VE | 1 |
| Arkadopoulos, NF | 1 |
| Guo, C | 2 |
| Hao, LJ | 1 |
| Yang, ZH | 1 |
| Chai, R | 1 |
| Zhang, S | 1 |
| Gao, HL | 1 |
| Zhong, ML | 1 |
| Wang, T | 2 |
| Li, JY | 1 |
| Wang, ZY | 2 |
| Zheng, M | 1 |
| Chen, G | 1 |
| He, XF | 1 |
| Lan, Y | 1 |
| Zhang, Q | 1 |
| Liu, DX | 1 |
| Wang, Q | 1 |
| Liang, FY | 1 |
| Zeng, JS | 1 |
| Xu, GQ | 1 |
| Pei, Z | 1 |
| Sun, YM | 1 |
| Wang, YT | 1 |
| Jiang, L | 1 |
| Xue, MZ | 1 |
| Sripetchwandee, J | 1 |
| Wongjaikam, S | 1 |
| Krintratun, W | 1 |
| Chattipakorn, N | 4 |
| Chattipakorn, SC | 1 |
| Hernandez, R | 1 |
| Sun, H | 1 |
| England, CG | 1 |
| Valdovinos, HF | 1 |
| Ehlerding, EB | 1 |
| Barnhart, TE | 1 |
| Yang, Y | 1 |
| Cai, W | 1 |
| LeBlanc, RH | 1 |
| Chen, R | 1 |
| Selim, MH | 1 |
| Hanafy, KA | 1 |
| Rudd, SE | 1 |
| Roselt, P | 1 |
| Cullinane, C | 1 |
| Hicks, RJ | 1 |
| Donnelly, PS | 1 |
| Mani, A | 1 |
| Staikou, C | 1 |
| Karmaniolou, I | 1 |
| Orfanos, N | 1 |
| Mylonas, A | 1 |
| Nomikos, T | 2 |
| Pafiti, A | 3 |
| Papalois, A | 1 |
| Arkadopoulos, N | 4 |
| Smyrniotis, V | 4 |
| Theodoraki, K | 2 |
| Li, Y | 1 |
| Pan, K | 1 |
| Chen, L | 2 |
| Ning, JL | 1 |
| Yang, T | 2 |
| Terrando, N | 1 |
| Tao, G | 1 |
| Benadiba, J | 1 |
| Rosilio, C | 1 |
| Nebout, M | 1 |
| Heimeroth, V | 1 |
| Neffati, Z | 1 |
| Popa, A | 1 |
| Mary, D | 1 |
| Griessinger, E | 1 |
| Imbert, V | 1 |
| Sirvent, N | 1 |
| Peyron, JF | 1 |
| Zou, X | 1 |
| Jiang, S | 1 |
| Wu, Z | 1 |
| Shi, Y | 2 |
| Cai, S | 1 |
| Zhu, R | 1 |
| Vlahakos, D | 1 |
| Kostopanagiotou, G | 3 |
| Panagopoulos, D | 1 |
| Karvouni, E | 1 |
| Routsi, C | 1 |
| Kalimeris, K | 3 |
| Andreadou, I | 1 |
| Kouskouni, E | 2 |
| Nevo, I | 1 |
| Sagi-Assif, O | 1 |
| Edry Botzer, L | 1 |
| Amar, D | 1 |
| Maman, S | 1 |
| Kariv, N | 1 |
| Leider-Trejo, LE | 1 |
| Savelyeva, L | 1 |
| Schwab, M | 1 |
| Yron, I | 1 |
| Witz, IP | 1 |
| Francisco, AF | 2 |
| de Abreu Vieira, PM | 2 |
| Arantes, JM | 2 |
| Pedrosa, ML | 2 |
| Martins, HR | 1 |
| Silva, M | 2 |
| Veloso, VM | 1 |
| de Lana, M | 1 |
| Bahia, MT | 1 |
| Tafuri, WL | 2 |
| Carneiro, CM | 2 |
| Otto-Duessel, M | 1 |
| Brewer, C | 1 |
| Gonzalez, I | 1 |
| Nick, H | 1 |
| Wood, JC | 1 |
| Selim, M | 1 |
| Song, S | 2 |
| He, Y | 3 |
| Wang, J | 2 |
| Wu, J | 1 |
| Bao, X | 1 |
| Huang, F | 1 |
| Wan, S | 1 |
| Zhan, R | 1 |
| Zheng, S | 1 |
| van der Kooij, MA | 1 |
| Groenendaal, F | 2 |
| Kavelaars, A | 1 |
| Heijnen, CJ | 1 |
| van Bel, F | 2 |
| Kocaoğlu, B | 1 |
| Akgun, U | 1 |
| Erol, B | 1 |
| Karahan, M | 1 |
| Yalçin, S | 1 |
| Nuhn, P | 2 |
| Künzli, BM | 2 |
| Hennig, R | 1 |
| Mitkus, T | 2 |
| Ramanauskas, T | 1 |
| Nobiling, R | 1 |
| Meuer, SC | 1 |
| Friess, H | 2 |
| Berberat, PO | 2 |
| Thangarajah, H | 1 |
| Yao, D | 1 |
| Chang, EI | 1 |
| Jazayeri, L | 1 |
| Vial, IN | 1 |
| Galiano, RD | 1 |
| Du, XL | 1 |
| Grogan, R | 1 |
| Galvez, MG | 1 |
| Januszyk, M | 1 |
| Brownlee, M | 1 |
| Kruzel, ML | 1 |
| Actor, JK | 1 |
| Radak, Z | 1 |
| Bacsi, A | 1 |
| Saavedra-Molina, A | 1 |
| Boldogh, I | 1 |
| Warkentin, LM | 1 |
| Auriat, AM | 2 |
| Wowk, S | 1 |
| Colbourne, F | 2 |
| Choy, MK | 1 |
| Movassagh, M | 1 |
| Bennett, MR | 1 |
| Foo, RS | 1 |
| Andrades, M | 2 |
| Ritter, C | 3 |
| de Oliveira, MR | 1 |
| Streck, EL | 6 |
| Sinis, N | 1 |
| Di Scipio, F | 1 |
| Schönle, P | 1 |
| Werdin, F | 1 |
| Kraus, A | 1 |
| Koopmanns, G | 1 |
| Masanneck, C | 1 |
| Hermanns, S | 1 |
| Danker, T | 1 |
| Guenther, E | 1 |
| Haerle, M | 1 |
| Schaller, HE | 1 |
| Geuna, S | 1 |
| Mueller, HW | 1 |
| Morgenstern, LB | 1 |
| Schallert, T | 2 |
| Najafzadeh, H | 1 |
| Jalali, MR | 1 |
| Morovvati, H | 1 |
| Taravati, F | 1 |
| Hod, EA | 1 |
| Zhang, N | 1 |
| Sokol, SA | 1 |
| Wojczyk, BS | 1 |
| Francis, RO | 1 |
| Ansaldi, D | 1 |
| Francis, KP | 1 |
| Della-Latta, P | 1 |
| Whittier, S | 1 |
| Sheth, S | 1 |
| Hendrickson, JE | 1 |
| Zimring, JC | 1 |
| Brittenham, GM | 3 |
| Spitalnik, SL | 1 |
| Barbosa, PR | 1 |
| Cardoso, MR | 1 |
| Daufenbach, JF | 1 |
| Gonçalves, CL | 1 |
| Machado, RA | 2 |
| Roza, CA | 1 |
| Scaini, G | 3 |
| Rezin, GT | 1 |
| Schuck, PF | 3 |
| Esparza, JL | 1 |
| Garcia, T | 1 |
| Gómez, M | 1 |
| Nogués, MR | 1 |
| Giralt, M | 1 |
| Domingo, JL | 1 |
| Tan, T | 1 |
| Scholz, PM | 1 |
| Weiss, HR | 2 |
| Nastos, C | 2 |
| Economou, E | 1 |
| Vaithilingam, V | 1 |
| Oberholzer, J | 1 |
| Guillemin, GJ | 1 |
| Tuch, BE | 1 |
| Elói-Santos, SM | 1 |
| Martins-Filho, OA | 1 |
| Teixeira-Carvalho, A | 1 |
| Araújo, MS | 1 |
| Liang, Y | 1 |
| Yang, QH | 1 |
| Yu, XD | 1 |
| Jiang, DM | 1 |
| Yang, H | 1 |
| Kumfu, S | 3 |
| Chattipakorn, S | 3 |
| Settakorn, J | 1 |
| Orestes, P | 1 |
| Bojadzic, D | 1 |
| Lee, J | 1 |
| Leach, E | 1 |
| Salajegheh, R | 1 |
| Digruccio, MR | 1 |
| Nelson, MT | 1 |
| Todorovic, SM | 1 |
| Papoutsidakis, N | 1 |
| Defterevos, G | 1 |
| Kalogeropoulou, H | 1 |
| Zerva, L | 1 |
| Santana-Rodríguez, N | 1 |
| Clavo, B | 1 |
| Llontop, P | 1 |
| López, A | 1 |
| García-Castellano, JM | 1 |
| Machín, RP | 1 |
| Ponce, MA | 1 |
| Fiuza, MD | 1 |
| García-Herrera, R | 1 |
| Brito, Y | 1 |
| Yordi, NA | 1 |
| Chirino, R | 1 |
| Lee, SA | 1 |
| Son, YO | 1 |
| Kook, SH | 1 |
| Choi, KC | 1 |
| Lee, JC | 1 |
| Lee, JY | 1 |
| Ernestus, RI | 1 |
| Wang, MM | 1 |
| Francés, DE | 1 |
| Ronco, MT | 1 |
| Ingaramo, PI | 1 |
| Monti, JA | 1 |
| Pisani, GB | 1 |
| Parody, JP | 1 |
| Pellegrino, JM | 1 |
| Carrillo, MC | 1 |
| Martín-Sanz, P | 1 |
| Carnovale, CE | 1 |
| Obolensky, A | 1 |
| Lederman, M | 1 |
| Bulvik, B | 1 |
| Alper-Pinus, R | 1 |
| Yaul, R | 1 |
| Deleon, E | 1 |
| Chowers, I | 1 |
| Banin, E | 1 |
| Chun, HJ | 1 |
| Kim, DW | 1 |
| Yi, HJ | 1 |
| Kim, YS | 1 |
| Kim, EH | 1 |
| Hwang, SJ | 1 |
| Jwa, CS | 1 |
| Lee, YK | 1 |
| Ryou, H | 1 |
| Rathnasamy, G | 1 |
| Ling, EA | 1 |
| Kaur, C | 1 |
| Silasi, G | 1 |
| Wei, Z | 1 |
| Paquette, R | 1 |
| Paterson, P | 1 |
| Nichol, H | 1 |
| Jung, M | 1 |
| Sola, A | 1 |
| Hughes, J | 1 |
| Kluth, DC | 1 |
| Vinuesa, E | 1 |
| Viñas, JL | 1 |
| Pérez-Ladaga, A | 1 |
| Hotter, G | 1 |
| Chinda, K | 1 |
| Teodorak, BP | 1 |
| Jeremias, IC | 1 |
| Morais, MO | 1 |
| Mina, F | 1 |
| Dominguini, D | 1 |
| Pescador, B | 1 |
| Comim, CM | 2 |
| Ferreira, GC | 2 |
| Im, DS | 1 |
| Jeon, JW | 1 |
| Lee, JS | 1 |
| Won, SJ | 1 |
| Cho, SI | 1 |
| Lee, YB | 1 |
| Gwag, BJ | 1 |
| Zhang, L | 1 |
| Li, M | 1 |
| Zhu, G | 1 |
| Lin, J | 1 |
| Al-Shabanah, OA | 1 |
| Aleisa, AM | 1 |
| Hafez, MM | 1 |
| Al-Rejaie, SS | 1 |
| Al-Yahya, AA | 1 |
| Bakheet, SA | 1 |
| Al-Harbi, MM | 1 |
| Sayed-Ahmed, MM | 1 |
| Zheng, W | 1 |
| Shan, ZY | 1 |
| Teng, WP | 1 |
| Ceyhan, GO | 1 |
| Bergmann, F | 1 |
| Fischer, L | 1 |
| Giese, N | 1 |
| Oliveira, GM | 1 |
| Pasquali, MA | 1 |
| Moreira, JC | 2 |
| Bogo, MR | 1 |
| Gao, Y | 1 |
| Wang, N | 1 |
| Ma, Z | 1 |
| Guan, P | 1 |
| Ma, J | 1 |
| Zhang, X | 1 |
| Zhang, J | 1 |
| Chu, L | 1 |
| Haleagrahara, N | 1 |
| Siew, CJ | 1 |
| Ponnusamy, K | 1 |
| Balogh, N | 1 |
| Krausz, F | 1 |
| Lévai, P | 1 |
| Ribiczeyné, PS | 1 |
| Vajdovich, P | 1 |
| Gaál, T | 1 |
| Chander, V | 1 |
| Singh, D | 1 |
| Chopra, K | 1 |
| Mahmoud, MS | 1 |
| Obejero-Paz, CA | 1 |
| Dong, WQ | 1 |
| Levy, MN | 1 |
| Kuryshev, YA | 1 |
| Brown, AM | 1 |
| Pelit, A | 1 |
| Haciyakupoglu, G | 1 |
| Zorludemir, S | 1 |
| Mete, U | 1 |
| Daglioglu, K | 1 |
| Kaya, M | 1 |
| Junxia, X | 1 |
| Hong, J | 1 |
| Wenfang, C | 1 |
| Ming, Q | 1 |
| Karayilanoğlu, T | 1 |
| Gunhan, O | 1 |
| Kenar, L | 1 |
| Kurt, B | 1 |
| Peeters-Scholte, C | 1 |
| van den Tweel, E | 1 |
| Chekanov, VS | 1 |
| Zargarian, M | 1 |
| Baibekov, I | 1 |
| Karakozov, P | 1 |
| Tchekanov, G | 1 |
| Hare, J | 1 |
| Nikolaychik, V | 1 |
| Bajwa, T | 1 |
| Akhtar, M | 1 |
| Barollo, M | 1 |
| D'Incà, R | 1 |
| Scarpa, M | 1 |
| Medici, V | 1 |
| Cardin, R | 1 |
| Fries, W | 1 |
| Angriman, I | 1 |
| Sturniolo, GC | 1 |
| Nakamura, T | 1 |
| Hoff, JT | 3 |
| Youdim, MB | 1 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Takeshita, K | 1 |
| Takajo, T | 1 |
| Hirata, H | 1 |
| Ono, M | 1 |
| Utsumi, H | 1 |
| Arimoto, T | 1 |
| Kadiiska, MB | 1 |
| Sato, K | 1 |
| Corbett, J | 1 |
| Kadkhodaee, M | 1 |
| Gol, A | 1 |
| Zhuang, J | 1 |
| Wang, Z | 2 |
| Gou, L | 1 |
| Mu, D | 1 |
| Chang, YS | 1 |
| Vexler, ZS | 1 |
| Ferriero, DM | 1 |
| Caputa, M | 1 |
| Rogalska, J | 1 |
| Wentowska, K | 1 |
| Nowakowska, A | 1 |
| da Cunha, AA | 1 |
| Echer, IC | 1 |
| Reinke, A | 1 |
| Lucchiari, N | 1 |
| Rocha, J | 1 |
| Menna-Barreto, S | 1 |
| Cross, CE | 1 |
| van Asbeck, BS | 1 |
| Halliwell, B | 2 |
| Golenser, J | 1 |
| Domb, A | 1 |
| Mordechai-Daniel, T | 1 |
| Leshem, B | 1 |
| Luty, A | 1 |
| Kremsner, P | 1 |
| Beard, JL | 1 |
| Wiesinger, JA | 1 |
| Jones, BC | 1 |
| Defrère, S | 1 |
| Van Langendonckt, A | 1 |
| Vaesen, S | 1 |
| Jouret, M | 1 |
| González Ramos, R | 1 |
| Gonzalez, D | 1 |
| Donnez, J | 1 |
| Damiani, CR | 1 |
| Benetton, CA | 1 |
| Stoffel, C | 1 |
| Bardini, KC | 1 |
| Cardoso, VH | 1 |
| Di Giunta, G | 1 |
| Pinho, RA | 1 |
| Chi, OZ | 1 |
| Hunter, C | 1 |
| Liu, X | 1 |
| Barichello, T | 1 |
| Constantino, L | 1 |
| Réus, GZ | 1 |
| Martins, MR | 1 |
| Petronilho, F | 1 |
| Fatemi, SJ | 1 |
| Amiri, A | 1 |
| Bazargan, MH | 1 |
| Tubafard, S | 1 |
| Fatemi, SN | 1 |
| Bloomer, SA | 1 |
| Brown, KE | 1 |
| Buettner, GR | 1 |
| Kregel, KC | 1 |
| Hishikawa, T | 1 |
| Ono, S | 1 |
| Ogawa, T | 1 |
| Tokunaga, K | 1 |
| Sugiu, K | 1 |
| Date, I | 1 |
| Jones, NM | 1 |
| Kardashyan, L | 1 |
| Callaway, JK | 1 |
| Lee, EM | 1 |
| Beart, PM | 1 |
| Li, YX | 1 |
| Ding, SJ | 1 |
| Xiao, L | 1 |
| Guo, W | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Kim, SJ | 1 |
| Lee, ST | 1 |
| Kim, J | 1 |
| Park, HK | 1 |
| Song, EC | 1 |
| Kim, SU | 1 |
| Kim, M | 1 |
| Lee, SK | 1 |
| Roh, JK | 1 |
| Yoshino, S | 1 |
| Blake, DR | 3 |
| Bacon, PA | 2 |
| McLaren, GD | 1 |
| Muir, WA | 1 |
| Kellermeyer, RW | 1 |
| Hall, ND | 1 |
| Dieppe, PA | 1 |
| Gutteridge, JM | 1 |
| Cheung, PJ | 1 |
| Nigrelli, RF | 1 |
| Ruggieri, GD | 1 |
| Gold, K | 1 |
| Baiardi, JC | 1 |
| Choi, YC | 1 |
| Hough, AJ | 1 |
| Morris, GM | 1 |
| Sokoloff, L | 1 |
| Merali, S | 1 |
| Chin, K | 1 |
| Grady, RW | 3 |
| Weissberger, L | 1 |
| Clarkson, AB | 2 |
| Lamarque, D | 1 |
| Whittle, BJ | 1 |
| Gehlbach, P | 1 |
| Purple, RL | 1 |
| Crapo, JD | 1 |
| LaLonde, C | 1 |
| Ikegami, K | 1 |
| Demling, R | 1 |
| Guy, J | 1 |
| McGorray, S | 1 |
| Qi, X | 1 |
| Fitzsimmons, J | 1 |
| Mancuso, A | 1 |
| Rao, N | 1 |
| Muntané, J | 2 |
| Puig-Parellada, P | 2 |
| Mitjavila, MT | 2 |
| Hurn, PD | 1 |
| Koehler, RC | 1 |
| Blizzard, KK | 1 |
| Traystman, RJ | 1 |
| Mustard, RA | 1 |
| Bohnen, JM | 1 |
| Mullen, JB | 1 |
| Schouten, BD | 1 |
| Swanson, HT | 1 |
| Turnage, RH | 1 |
| Magee, JC | 1 |
| Guice, KS | 1 |
| Myers, SI | 1 |
| Oldham, KT | 1 |
| Bilgihan, A | 1 |
| Türközkan, N | 1 |
| Aricioğlu, A | 1 |
| Aykol, S | 1 |
| Cevik, C | 1 |
| Göksel, M | 2 |
| Colletti, LM | 1 |
| Remick, DG | 1 |
| Campbell, DA | 1 |
| Nankivell, BJ | 1 |
| Boadle, RA | 1 |
| Harris, DC | 1 |
| Watanabe, BI | 1 |
| Limm, W | 1 |
| Suehiro, A | 1 |
| Suehiro, G | 1 |
| Premaratne, S | 1 |
| McNamara, JJ | 1 |
| Fernandez, Y | 1 |
| Mitjavila, S | 1 |
| Adamson, IY | 1 |
| Sienko, A | 1 |
| Tenenbein, M | 1 |
| Vollrath, B | 1 |
| Chan, P | 1 |
| Findlay, M | 1 |
| Cook, D | 1 |
| Chagas, AC | 1 |
| Pileggi, F | 1 |
| Lopes, EA | 1 |
| Da-Luz, PL | 1 |
| Dean, BS | 1 |
| Oehme, FW | 1 |
| Krenzelok, EP | 1 |
| Griffith, GR | 1 |
| Hines, RH | 1 |
| Ueda, N | 1 |
| Baliga, R | 1 |
| Shah, SV | 1 |
| Yokel, RA | 1 |
| Meurer, KA | 1 |
| Skinner, TL | 1 |
| Fredenburg, AM | 1 |
| Utkan, T | 1 |
| Sarioglu, Y | 1 |
| Kaya, T | 1 |
| Akgün, M | 1 |
| Solak, O | 1 |
| Florence, AL | 1 |
| Gauthier, A | 1 |
| Ward, RJ | 2 |
| Crichton, RR | 2 |
| Bhattacharya, M | 1 |
| Ponka, P | 1 |
| Hardy, P | 1 |
| Hanna, N | 1 |
| Varma, DR | 1 |
| Lachapelle, P | 1 |
| Chemtob, S | 1 |
| Minina, LT | 1 |
| Prostakova, TM | 1 |
| Meshchano, AIu | 1 |
| Kol'tsova, GN | 1 |
| Bovenko, VN | 1 |
| Köksoy, FN | 1 |
| Köse, H | 1 |
| Soybír, GR | 1 |
| Yalçin, O | 2 |
| Cokneşelí, B | 1 |
| Gupta, R | 1 |
| Gupta, S | 1 |
| Joshi, K | 1 |
| Ganguly, NK | 1 |
| Siganos, CS | 1 |
| Frucht-Pery, J | 1 |
| Muallem, MS | 1 |
| Naoumidi, I | 1 |
| Ever-Hadani, P | 1 |
| Pallikaris, IG | 1 |
| Siganos, DS | 1 |
| Dolganova, A | 1 |
| Sharonov, BP | 1 |
| Soybir, G | 1 |
| Köksoy, F | 1 |
| Ekiz, F | 1 |
| Fincan, K | 1 |
| Haklar, G | 1 |
| Yüksel, M | 1 |
| Yoo, YM | 1 |
| Kim, SS | 1 |
| Han, JA | 1 |
| Lea, HZ | 1 |
| Kim, YM | 1 |
| Auer, M | 1 |
| Pfister, LA | 1 |
| Leppert, D | 1 |
| Täuber, MG | 1 |
| Leib, SL | 1 |
| Chatterjee, PK | 1 |
| Cuzzocrea, S | 1 |
| Brown, PA | 1 |
| Zacharowski, K | 1 |
| Stewart, KN | 1 |
| Mota-Filipe, H | 1 |
| Thiemermann, C | 1 |
| Rose, S | 1 |
| Pizanis, A | 1 |
| Silomon, M | 1 |
| Karck, M | 1 |
| Tanaka, S | 1 |
| Sturm, C | 1 |
| Haverich, A | 1 |
| Paxian, M | 1 |
| Rensing, H | 1 |
| Rickauer, A | 1 |
| Schönhofen, S | 1 |
| Schmeck, J | 1 |
| Pannen, BH | 1 |
| Bauer, I | 1 |
| Bauer, M | 1 |
| Jiang, H | 1 |
| Chen, WF | 1 |
| Xie, JX | 1 |
| Huang, FP | 1 |
| Nemoianu, A | 1 |
| Hershko, C | 1 |
| Link, G | 1 |
| Konijn, AM | 1 |
| Huerta, M | 1 |
| Rosenmann, E | 1 |
| Reinus, C | 1 |
| Bergeron, RJ | 1 |
| Wiegand, J | 1 |
| Ozdemir, E | 1 |
| Dokucu, AI | 1 |
| Uzunlar, AK | 1 |
| Ece, A | 1 |
| Yaldiz, M | 1 |
| Oztürk, H | 1 |
| Steinling, M | 1 |
| Marchandise, X | 1 |
| Boidein, M | 1 |
| Vie, MC | 1 |
| Vergnes, R | 1 |
| Hess, JL | 1 |
| Bunce, GE | 1 |
| Lantz, GC | 1 |
| Badylak, SF | 1 |
| Hiles, MC | 1 |
| Arkin, TE | 1 |
| Florence, A | 1 |
| Peters, TJ | 1 |
| de los Toyos, JR | 1 |
| Menéndez, P | 1 |
| Sampedro, A | 1 |
| Hardisson, C | 1 |
| Niederau, C | 1 |
| Niederau, M | 1 |
| Borchard, F | 1 |
| Ude, K | 1 |
| Lüthen, R | 1 |
| Strohmeyer, G | 1 |
| Ferrell, LD | 1 |
| Grendell, JH | 1 |
| Verbeelen, D | 2 |
| Fleckenstein, AE | 1 |
| Smith, SL | 1 |
| Linseman, KL | 1 |
| Beuving, LJ | 1 |
| Hall, ED | 1 |
| Vollmer, DG | 1 |
| Hongo, K | 1 |
| Ogawa, H | 1 |
| Tsukahara, T | 1 |
| Kassell, NF | 1 |
| Manson, PN | 1 |
| Jesudass, R | 1 |
| Marzella, L | 1 |
| Bulkley, GB | 1 |
| Im, MJ | 1 |
| Narayan, KK | 1 |
| Sarić, M | 1 |
| Curry, SC | 1 |
| Bond, GR | 1 |
| Raschke, R | 1 |
| Tellez, D | 1 |
| Wiggins, D | 1 |
| Good, PA | 1 |
| Claxson, A | 1 |
| Morris, CJ | 1 |
| Wolfe, LC | 1 |
| Nicolosi, RJ | 1 |
| Renaud, MM | 1 |
| Finger, J | 1 |
| Hegsted, M | 1 |
| Peter, H | 1 |
| Nathan, DG | 1 |
| Mahoney, JR | 1 |
| Hallaway, PE | 1 |
| Hedlund, BE | 1 |
| Eaton, JW | 1 |
| McCord, JM | 1 |
| Russell, WJ | 1 |
| Smeyers-Verbeke, J | 1 |
| van Hooff, I | 1 |
| de Roy, G | 1 |
| Rao, NA | 1 |
| Romero, JL | 1 |
| Fernandez, MA | 1 |
| Sevanian, A | 1 |
| Marak, GE | 1 |
| Babbs, CF | 1 |
| Paller, MS | 1 |
| Wainstock de Calmanovici, R | 1 |
| Billi, SC | 1 |
| Aldonatti, CA | 1 |
| San Martín de Viale, LC | 1 |
| Corden, BJ | 1 |
| Myers, CL | 1 |
| Weiss, SJ | 1 |
| Kirsh, MM | 1 |
| Shlafer, M | 1 |
| King, RG | 1 |
| Graziano, JH | 1 |
| Cerami, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Efficacy and Safety of NestaCell® in Moderated Huntington's Disease[NCT06097780] | Phase 3 | 120 participants (Anticipated) | Interventional | 2024-06-08 | Not yet recruiting | ||
| Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225] | Phase 2 | 294 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP)[NCT02854722] | Phase 2 | 10 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | ||
| Safety of Surgical Treatment In Severe Primary Pontine Hemorrhage Evacuation (STIPE): a Multicentric, Randomized, Controlled, Open-label Trial[NCT04647162] | 64 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 0 |
Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 1 |
| Normal Saline | 2 |
Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 4 |
Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 9 |
| Normal Saline | 5 |
Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 39 |
| Normal Saline | 49 |
Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 24 |
| Normal Saline | 26 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 61 |
| Normal Saline | 48 |
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 48 |
| Normal Saline | 47 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 97 |
| Normal Saline | 92 |
"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 91 |
| Normal Saline | 82 |
Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| All cause | Cause by acute respiratory distress syndrome | |
| Deferoxamine Mesylate | 20 | 2 |
| Normal Saline | 23 | 1 |
Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Onset to treatment time <=12 hours | Onset to treatment time >12 hours | |
| Deferoxamine Mesylate | 15 | 33 |
| Normal Saline | 19 | 28 |
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 3 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 1 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 9 |
| Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 12 |
| Normal Saline | 14 |
7 reviews available for deferoxamine and Disease Models, Animal
| Article | Year |
|---|---|
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2021 |
Emerging roles of ferroptosis in liver pathophysiology.
Topics: Animals; Antineoplastic Agents; Caffeic Acids; Carcinoma, Hepatocellular; Cycloheximide; Cyclohexyla | 2020 |
Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Overload; Iron-R | 2015 |
Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis.
Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Mice; Rats; Siderophores; Swine; | 2015 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob | 2009 |
Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
Topics: Anemia, Hypochromic; Biological Transport; Bloodletting; Chelating Agents; Deferoxamine; Disease Mod | 1983 |
Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury.
Topics: Animals; Coronary Vessels; Deferoxamine; Disease Models, Animal; Dogs; Free Radicals; Iron; Myocardi | 1995 |
235 other studies available for deferoxamine and Disease Models, Animal
| Article | Year |
|---|---|
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C | 2016 |
UAMC-3203 or/and Deferoxamine Improve Post-Resuscitation Myocardial Dysfunction Through Suppressing Ferroptosis in a Rat Model of Cardiac Arrest.
Topics: Animals; Cardiopulmonary Resuscitation; Cyclohexylamines; Deferoxamine; Disease Models, Animal; Ferr | 2022 |
Kidney tubule iron loading in experimental focal segmental glomerulosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Deferoxamine; Disease Models, Animal; | 2022 |
Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models.
Topics: Alzheimer Disease; Animals; Deferasirox; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Ch | 2022 |
HIF-1α and VEGF Are Involved in Deferoxamine-Ameliorated Traumatic Brain Injury.
Topics: Animals; Apoptosis; Behavior, Animal; Brain; Brain Injuries, Traumatic; Deferoxamine; Disease Models | 2020 |
Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure.
Topics: Acetaminophen; alpha-Tocopherol; Animals; Antioxidants; Coenzyme A Ligases; Cyclohexylamines; Cycloo | 2020 |
Endothelial HIF-2α as a Key Endogenous Mediator Preventing Emphysema.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Deferoxamine; Diseas | 2020 |
Involvement of oxidative stress-induced annulus fibrosus cell and nucleus pulposus cell ferroptosis in intervertebral disc degeneration pathogenesis.
Topics: Animals; Annulus Fibrosus; Autophagy; Carbolines; Case-Control Studies; Cells, Cultured; Deferoxamin | 2021 |
Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis.
Topics: Animals; Cell Line; Deferoxamine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; | 2021 |
Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis.
Topics: Animals; Bleomycin; Cation Transport Proteins; Deferoxamine; Disease Models, Animal; Ferroptosis; Ge | 2021 |
Neurological impairment caused by Schistosoma mansoni systemic infection exhibits early features of idiopathic neurodegenerative disease.
Topics: Acetylcysteine; Animals; Anthelmintics; Astrocytes; Deferoxamine; Disease Models, Animal; Free Radic | 2021 |
CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Cell Death; Cerebral Hemorr | 2017 |
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; | 2017 |
Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Blood Glucose; | 2017 |
Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice.
Topics: Animals; Bone Density; Cancellous Bone; Cell Differentiation; Deferoxamine; Disease Models, Animal; | 2017 |
Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cognition; Deferoxamine; Disease Model | 2017 |
Detection and inhibition of lipid-derived radicals in low-density lipoprotein.
Topics: 4-Chloro-7-nitrobenzofurazan; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferas | 2017 |
Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Topics: Animals; Deferoxamine; Disease Models, Animal; Female; Ferritins; Human Umbilical Vein Endothelial C | 2018 |
Zebrafish larvae as a model to demonstrate secondary iron overload.
Topics: Animals; beta-Thalassemia; Chelation Therapy; Deferoxamine; Disease Models, Animal; Immunohistochemi | 2018 |
Targeting Germinal Matrix Hemorrhage-Induced Overexpression of Sodium-Coupled Bicarbonate Exchanger Reduces Posthemorrhagic Hydrocephalus Formation in Neonatal Rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Cerebral Hemorrhage; Cerebrospinal Fluid; Chlorides; Ch | 2018 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therap | 2018 |
Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles
Topics: Animals; Antifungal Agents; Azoles; Candida; Candida albicans; Deferiprone; Deferoxamine; Disease Mo | 2018 |
Effects of amniotic membrane extract and deferoxamine on angiogenesis in wound healing: an in vivo model.
Topics: Amnion; Angiogenesis Inducing Agents; Animals; Deferoxamine; Disease Models, Animal; Drug Synergism; | 2018 |
Topical Deferoxamine Alleviates Skin Injury and Normalizes Atomic Force Microscopy Patterns Following Radiation in a Murine Breast Reconstruction Model.
Topics: Administration, Topical; Animals; Back; Deferoxamine; Disease Models, Animal; Female; Microscopy, At | 2018 |
Deferoxamine preconditioning ameliorates mechanical ventilation-induced lung injury in rat model via ROS in alveolar macrophages: a randomized controlled study.
Topics: Animals; Deferoxamine; Disease Models, Animal; Edema; Lung; Macrophages, Alveolar; Male; Mitochondri | 2018 |
Deferoxamine can prevent pressure ulcers and accelerate healing in aged mice.
Topics: Administration, Cutaneous; Animals; Deferoxamine; Disease Models, Animal; Mice; Mice, Inbred C57BL; | 2018 |
Effects of iron chelating agent on Schistosoma mansoni infected murine model.
Topics: Animals; Deferoxamine; Disease Models, Animal; Granuloma; Iron Chelating Agents; Liver Cirrhosis; Li | 2019 |
Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction.
Topics: Administration, Topical; Animals; Breast Neoplasms; Deferoxamine; Disease Models, Animal; Female; Ma | 2019 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels.
Topics: Animals; Antioxidants; Catalepsy; Corpus Striatum; Deferoxamine; Dextromethorphan; Disease Models, A | 2019 |
Thermo-sensitive keratin hydrogel against iron-induced brain injury after experimental intracerebral hemorrhage.
Topics: Acrylic Resins; Adsorption; Animals; Behavior, Animal; Brain; Brain Injuries; Cerebral Hemorrhage; D | 2019 |
Role of iron in brain lipocalin 2 upregulation after intracerebral hemorrhage in rats.
Topics: Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Functional Laterality; Gl | 2013 |
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelo | 2013 |
Deferoxamine restores callus size, mineralization, and mechanical strength in fracture healing after radiotherapy.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Calcification, Physiologic; Deferoxamine; Disease Mod | 2013 |
The ameliorative effect of various antioxidants on Adriamycin-induced fetal renal abnormalities.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antioxidants; Deferoxamine; Disease Models, Animal | 2013 |
Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Topics: Animals; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Disease Models, Animal; Dose-Respo | 2016 |
Altered iron homeostasis in an animal model of hypertensive nephropathy: stroke-prone rats.
Topics: Animals; Blood Pressure; Deferoxamine; Disease Models, Animal; Hemolysis; Homeostasis; Hypertension, | 2013 |
Iron accumulates in Huntington's disease neurons: protection by deferoxamine.
Topics: Animals; Corpus Striatum; Deferoxamine; Disease Models, Animal; Female; Huntington Disease; Injectio | 2013 |
Deferoxamine reduces neuronal death and hematoma lysis after intracerebral hemorrhage in aged rats.
Topics: Age Factors; Animals; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Ferriti | 2013 |
Sickle cell anemia: the impact of discovery, politics, and business.
Topics: Anemia, Sickle Cell; Animals; Cost Savings; Deferoxamine; Disease Models, Animal; Drug Delivery Syst | 2013 |
Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.
Topics: Animals; Biocompatible Materials; Cell Survival; Chelating Agents; Complement Activation; Deferoxami | 2013 |
Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model.
Topics: Animals; Bone and Bones; Cell Differentiation; Deferoxamine; Disease Models, Animal; Iron Overload; | 2014 |
Desferrioxamine effectively attenuates testicular tissue at the end of 3 h of ischemia but not in an equal period of reperfusion.
Topics: Animals; Deferoxamine; Disease Models, Animal; Follow-Up Studies; Male; Rats; Rats, Sprague-Dawley; | 2014 |
Deferoxamine enhances bone regeneration in mandibular distraction osteogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Bone Regeneration; Cell Proliferation; Deferoxamine; Disease | 2014 |
Iron-induced oxidative rat liver injury after non-heart-beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine.
Topics: Adenosine; Allopurinol; Animals; Aspartate Aminotransferases; Bile; Deferoxamine; Disease Models, An | 2014 |
Targeting angiogenesis as a therapeutic means to reinforce osteocyte survival and prevent nonunions in the aftermath of radiotherapy.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Cell Survival; Cells, Cultured; Deferoxamine; Disease | 2015 |
Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Disease Models, Animal; Female; | 2014 |
Brain CD47 expression in a swine model of intracerebral hemorrhage.
Topics: Animals; Astrocytes; Brain; CD47 Antigen; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; | 2014 |
Acute and delayed deferoxamine treatment attenuates long-term sequelae after germinal matrix hemorrhage in neonatal rats.
Topics: Animals; Animals, Newborn; Brain; Deferoxamine; Disease Models, Animal; Intracranial Hemorrhages; Ma | 2014 |
Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease.
Topics: Animals; Brain; Curcumin; Deferoxamine; Disease Models, Animal; Dopamine; Drug Interactions; Male; N | 2014 |
Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; De | 2014 |
Role of hemoglobin and iron in hydrocephalus after neonatal intraventricular hemorrhage.
Topics: Animals; Animals, Newborn; Blotting, Western; Cerebral Hemorrhage; Deferoxamine; Disease Models, Ani | 2014 |
Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition.
Topics: Animals; Blotting, Western; Brain; Cerebral Hemorrhage; Chronic Disease; Deferoxamine; Disease Model | 2015 |
Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus.
Topics: Abscess; Animal Structures; Animals; Bacterial Load; Deferoxamine; Disease Models, Animal; Female; I | 2014 |
Pyrophosphate-mediated iron acquisition from transferrin in Neisseria meningitidis does not require TonB activity.
Topics: Animals; Bacterial Proteins; Biological Transport; Deferoxamine; Diphosphates; Disease Models, Anima | 2014 |
The effect of deferoxamine on angiogenesis and bone repair in steroid-induced osteonecrosis of rabbit femoral heads.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Regeneration; Deferoxamine; Disease Models, Animal; Femu | 2015 |
The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model.
Topics: Animals; Chemistry, Pharmaceutical; Deferoxamine; Disease Models, Animal; Drug Stability; Humans; Is | 2015 |
Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model.
Topics: Animals; Deferoxamine; Disease Models, Animal; Male; Radiation Injuries; Rats; Rats, Sprague-Dawley; | 2015 |
Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice.
Topics: Animals; Caspase 3; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Encephal | 2015 |
Deferoxamine reduces intracerebral hemorrhage-induced white matter damage in aged rats.
Topics: Aging; Analysis of Variance; Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Dos | 2015 |
The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania.
Topics: Acetylcysteine; Aldehydes; Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Brain; | 2015 |
Pharmacological Suppression of CNS Scarring by Deferoxamine Reduces Lesion Volume and Increases Regeneration in an In Vitro Model for Astroglial-Fibrotic Scarring and in Rat Spinal Cord Injury In Vivo.
Topics: Animals; Astrocytes; Axons; Central Nervous System; Cicatrix; Collagen Type IV; Cyclic AMP; Deferoxa | 2015 |
Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington's disease models.
Topics: Animals; Caspases; Cell Line; Cluster Analysis; Connectome; Deferoxamine; Disease Models, Animal; Dr | 2016 |
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Topics: Animals; Antibodies, Bispecific; CD8 Antigens; CD8-Positive T-Lymphocytes; Colonic Neoplasms; Defero | 2016 |
Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; CA-19-9 Antigen; Cell Line, Tumor; Deferoxamine; Disease Models, An | 2015 |
Hypoxia induces NO-dependent release of heparan sulfate in fibroblasts from the Alzheimer mouse Tg2576 by activation of nitrite reduction.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal; Ascorbic Acid; Cell Hypoxia; Deferoxamine; Disea | 2016 |
A precursor-inducible zebrafish model of acute protoporphyria with hepatic protein aggregation and multiorganelle stress.
Topics: Aminolevulinic Acid; Animals; Deferoxamine; Disease Models, Animal; Genetic Predisposition to Diseas | 2016 |
The effects of antioxidants on a porcine model of liver hemorrhage.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Crystalloid Solutions; Deferoxamine; Disease Model | 2016 |
Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Deferoxamine; Disease | 2016 |
Hematoma Changes During Clot Resolution After Experimental Intracerebral Hemorrhage.
Topics: Animals; Complement Membrane Attack Complex; Deferoxamine; Disease Models, Animal; Hematoma; Hemolys | 2016 |
Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages.
Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Deferoxamine; Dendrites; Disease Models, Animal; | 2016 |
The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats.
Topics: Animals; Brain; Cell Death; Cerebral Hemorrhage; Cytoprotection; Deferoxamine; Disease Models, Anima | 2016 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasir | 2016 |
CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Hepatocellular; CD146 Antigen; Cell Line; Deferoxamine; | 2016 |
Heme oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via intracerebroventricular deferoxamine.
Topics: Animals; Calcium-Binding Proteins; Cells, Cultured; Cognition Disorders; Deferoxamine; Disease Model | 2016 |
A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Diseas | 2016 |
N-Acetylcysteine and Desferoxamine Reduce Pulmonary Oxidative Stress Caused by Hemorrhagic Shock in a Porcine Model.
Topics: Acetylcysteine; Animals; Biomarkers; Colloids; Crystalloid Solutions; Deferoxamine; Disease Models, | 2017 |
Deferoxamine regulates neuroinflammation and iron homeostasis in a mouse model of postoperative cognitive dysfunction.
Topics: Animals; Cell Line, Transformed; Cognition Disorders; Conditioning, Psychological; Deferoxamine; Dis | 2016 |
Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
Topics: Animals; Antigens, CD; Apoptosis; Asparaginase; Cell Line, Tumor; Cell Survival; Cells, Cultured; Ch | 2017 |
Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain; Chlorides; Deferoxamine; Disease Models, Animal; | 2017 |
Iron chelation attenuates intracranial pressure and improves survival in a swine model of acute liver failure.
Topics: Animals; Brain; Central Venous Pressure; Cytokines; Deferoxamine; Disease Models, Animal; Female; In | 2008 |
Generation and characterization of novel local and metastatic human neuroblastoma variants.
Topics: Adrenal Gland Neoplasms; Animals; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Disease Models | 2008 |
Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.
Topics: Analysis of Variance; Animals; Chagas Disease; Deferoxamine; Disease Models, Animal; Drug Therapy, C | 2008 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Dr | 2008 |
Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Brain Edema; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease M | 2008 |
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats.
Topics: Animals; Brain; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Enzyme Activ | 2008 |
Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron.
Topics: Analysis of Variance; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Enz | 2009 |
Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia-induced brain injury in the neonatal rat?
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Antioxidants; Brain Infarction; Caspase 3; Cere | 2009 |
Preventing blood-induced joint damage with the use of intra-articular iron chelators: an experimental study in rabbits.
Topics: Animals; Blood; Cartilage, Articular; Deferoxamine; Disease Models, Animal; Injections, Intra-Articu | 2009 |
Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo.
Topics: Analysis of Variance; Animals; Biliverdine; Carbon Monoxide; Cell Line, Tumor; Cell Proliferation; C | 2009 |
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.
Topics: Animals; Cells, Cultured; Deferoxamine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus | 2009 |
Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model.
Topics: Animals; Deferoxamine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Immunologic; | 2010 |
Failure of deferoxamine, an iron chelator, to improve outcome after collagenase-induced intracerebral hemorrhage in rats.
Topics: Animals; Behavior, Animal; Brain Edema; Brain Infarction; Cerebral Hemorrhage; Chelating Agents; Col | 2010 |
PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
Topics: Animals; Cardiomegaly; Cell Line; Cell Size; Chromones; Deferoxamine; Disease Models, Animal; Fibrob | 2010 |
Antioxidant treatment reverses organ failure in rat model of sepsis: role of antioxidant enzymes imbalance, neutrophil infiltration, and oxidative stress.
Topics: Acetylcysteine; Animals; Antioxidants; Catalase; Deferoxamine; Disease Models, Animal; Kidney; Lung; | 2011 |
Local administration of DFO-loaded lipid particles improves recovery after end-to-end reconstruction of rat median nerve.
Topics: Analysis of Variance; Animals; Body Weight; Deferoxamine; Disease Models, Animal; Electric Stimulati | 2009 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.
Topics: Administration, Oral; Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug | 2010 |
Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation.
Topics: Acute-Phase Reaction; Animals; Blood Preservation; Deferoxamine; Disease Models, Animal; Endotoxemia | 2010 |
Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine.
Topics: Acetylcysteine; Animals; Cell Respiration; Deferoxamine; Disease Models, Animal; Drug Combinations; | 2010 |
Role of deferoxamine on enzymatic stress markers in an animal model of Alzheimer's disease after chronic aluminum exposure.
Topics: Aluminum; Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Brain Chemistry; Che | 2011 |
Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.
Topics: Animals; Carbazoles; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Deferoxamine; D | 2010 |
Iron chelation for amelioration of liver ischemia-reperfusion injury.
Topics: Adult; Aged; Aged, 80 and over; Animals; Deferoxamine; Disease Models, Animal; Female; Humans; Iron | 2010 |
Beneficial effects of desferrioxamine on encapsulated human islets--in vitro and in vivo study.
Topics: Animals; Apoptosis; Blood Glucose; Cadaver; Caspases; Cell Line; Cell Survival; Deferoxamine; Diabet | 2010 |
Increase of reactive oxygen species by desferrioxamine during experimental Chagas' disease.
Topics: Animals; Antioxidants; Chagas Disease; Deferoxamine; Disease Models, Animal; Iron Chelating Agents; | 2010 |
Additive effect of tetramethylpyrazine and deferoxamine in the treatment of spinal cord injury caused by aortic cross-clamping in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Abdominal; Deferoxamine; Disease Models, An | 2011 |
Protective effect of deferoxamine on experimental spinal cord injury in rat.
Topics: Animals; Deferoxamine; Disease Models, Animal; Hindlimb; Injections, Intraperitoneal; Laminectomy; O | 2011 |
T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice.
Topics: Animals; beta-Thalassemia; Calcium Channels, T-Type; Cell Survival; Cells, Cultured; Deferoxamine; D | 2011 |
Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway.
Topics: Adrenochrome; Analgesics, Non-Narcotic; Animals; Calcium Channel Blockers; Calcium Channels, T-Type; | 2011 |
Antioxidant treatment attenuates intestinal mucosal damage and gut barrier dysfunction after major hepatectomy. Study in a porcine model.
Topics: Animals; Antioxidants; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Femal | 2011 |
Estradiol worsens the syndrome of ischemia-reperfusion injury in an experimental lung transplantation model.
Topics: Animals; Antioxidants; Chi-Square Distribution; Deferoxamine; Disease Models, Animal; Estradiol; Gra | 2011 |
Ascorbic acid increases the activity and synthesis of tyrosinase in B16F10 cells through activation of p38 mitogen-activated protein kinase.
Topics: alpha-MSH; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Deferoxamine; Disease Mo | 2011 |
Deferoxamine reduces early brain injury following subarachnoid hemorrhage.
Topics: Analysis of Variance; Animals; Brain; Brain Injuries; Deferoxamine; Disease Models, Animal; DNA Dama | 2011 |
Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage.
Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; DNA Damage; Frontal Lobe; In Sit | 2011 |
Hemoglobin expression in neurons and glia after intracerebral hemorrhage.
Topics: Animals; Cells, Cultured; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Embryo, Mammali | 2011 |
Deferoxamine reduces cavity size in the brain after intracerebral hemorrhage in aged rats.
Topics: Aging; Animals; Antigens, Differentiation; Behavior, Animal; Brain Infarction; Cell Count; Cerebral | 2011 |
Role of reactive oxygen species in the early stages of liver regeneration in streptozotocin-induced diabetic rats.
Topics: Animals; Cyclic N-Oxides; Deferoxamine; Diabetes Mellitus, Experimental; Disease Models, Animal; Hep | 2011 |
Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa.
Topics: Animals; Biomarkers; Chelating Agents; Cyclic Nucleotide Phosphodiesterases, Type 6; Deferoxamine; D | 2011 |
Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Atrophy; Brain Edema; CD11b Antigen; Cerebral Hemorrhage; Deferoxamin | 2012 |
Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species.
Topics: Animals; Animals, Newborn; Cell Death; Cell Proliferation; Cells, Cultured; Cerebral Cortex; Cytokin | 2011 |
Ferric iron chelation lowers brain iron levels after intracerebral hemorrhage in rats but does not improve outcome.
Topics: Analysis of Variance; Animals; Brain; Calcium; Cerebral Hemorrhage; Deferoxamine; Disease Models, An | 2012 |
Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2.
Topics: Acute Kidney Injury; Adoptive Transfer; Animals; Blood Urea Nitrogen; Cell Survival; Deferoxamine; D | 2012 |
T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice.
Topics: Animals; Azoles; Base Sequence; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels, L-Type | 2012 |
Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease.
Topics: Acetylcysteine; Amino Acids, Branched-Chain; Animals; Antioxidants; Deferoxamine; Disease Models, An | 2012 |
Role of the NMDA receptor and iron on free radical production and brain damage following transient middle cerebral artery occlusion.
Topics: Animals; Brain Damage, Chronic; Deferoxamine; Disease Models, Animal; Dizocilpine Maleate; Free Radi | 2012 |
Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury.
Topics: Analysis of Variance; Animals; Apoferritins; Atrophy; Brain; Brain Injuries; Deferoxamine; Disease M | 2013 |
Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model.
Topics: Animals; Cardiotoxins; Deferoxamine; Disease Models, Animal; Doxorubicin; Gene Expression Regulation | 2012 |
Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, An | 2013 |
Heme oxygenase 1-generated carbon monoxide and biliverdin attenuate the course of experimental necrotizing pancreatitis.
Topics: Animals; Anti-Inflammatory Agents; Ascites; Biliverdine; Carbon Monoxide; Deferoxamine; Disease Mode | 2013 |
Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels.
Topics: Animals; Azoles; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-T | 2013 |
Chronic administration of branched-chain amino acids impairs spatial memory and increases brain-derived neurotrophic factor in a rat model.
Topics: Acetylcysteine; Amino Acids, Branched-Chain; Animals; Antioxidants; Brain-Derived Neurotrophic Facto | 2013 |
Mechanism of protective effects of Danshen against iron overload-induced injury in mice.
Topics: Alanine Transaminase; Animals; Animals, Outbred Strains; Anti-Inflammatory Agents, Non-Steroidal; Ap | 2013 |
Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Deferoxamine; Disease Models, Animal; Dopamine; Drug The | 2013 |
Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats.
Topics: Animals; Arginine; Deferoxamine; Disease Models, Animal; Enzyme Inhibitors; Erythrocytes; Female; Gl | 2002 |
Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Disease Models, Animal; Glycerol; Iron Chelating Agents; | 2003 |
Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Topics: Acute Disease; Animals; Antiprotozoal Agents; Deferoxamine; Disease Models, Animal; Drug Therapy, Co | 1999 |
Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma.
Topics: Animals; Deferoxamine; Disease Models, Animal; Hematoma; Iron Chelating Agents; Nerve Degeneration; | 2003 |
Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Caudate Nucleus; Chlorides; Deferoxamine; Disease Models, An | 2003 |
The protective and therapeutic effects of zinc chloride and desferrioxamine on skin exposed to nitrogen mustard.
Topics: Animals; Biopsy; Burns, Chemical; Chemical Warfare Agents; Chlorides; Deferoxamine; Dermatologic Age | 2003 |
Redox state of near infrared spectroscopy-measured cytochrome aa(3) correlates with delayed cerebral energy failure following perinatal hypoxia-ischaemia in the newborn pig.
Topics: Allopurinol; Animals; Animals, Newborn; Biotin; Brain; Cell Survival; Deferoxamine; Disease Models, | 2004 |
Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia.
Topics: Animals; Blood Pressure; Collateral Circulation; Deferoxamine; Disease Models, Animal; Drug Therapy, | 2003 |
Effects of iron deprivation or chelation on DNA damage in experimental colitis.
Topics: Animals; Colitis; Deferoxamine; Diarrhea; Diet; Disease Models, Animal; DNA Adducts; DNA Damage; Iro | 2004 |
Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage.
Topics: Animals; Blotting, Western; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
In vivo oxygen radical generation in the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study.
Topics: Animals; Antifungal Agents; Catalase; Deferoxamine; Disease Models, Animal; Electron Spin Resonance | 2004 |
Synergistic production of lung free radicals by diesel exhaust particles and endotoxin.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Deferoxamine; Disease | 2005 |
The role of nitric oxide in iron-induced rat renal injury.
Topics: Animals; Arginine; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitor | 2004 |
[Putative mechanism of experimental immunological liver injury and influence of iron low-load on the injury in rat].
Topics: Animals; Deferoxamine; Disease Models, Animal; Iron; Iron Deficiencies; Lipid Peroxidation; Lipopoly | 2004 |
Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke.
Topics: Animals; Animals, Newborn; Blotting, Western; Deferoxamine; Disease Models, Animal; Erythropoietin; | 2005 |
Perinatal asphyxia, hyperthermia and hyperferremia as factors inducing behavioural disturbances in adulthood: a rat model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Asphyxia; Attention Deficit and Disruptive Behavior | 2005 |
Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat.
Topics: Acetylcysteine; Animals; Bronchoalveolar Lavage Fluid; Deferoxamine; Disease Models, Animal; Interle | 2006 |
More antioxidants in sepsis: still paved with uncertainties.
Topics: Acetylcysteine; Animals; Bronchoalveolar Lavage Fluid; Deferoxamine; Disease Models, Animal; Humans; | 2006 |
Iron chelators: correlation between effects on Plasmodium spp. and immune functions.
Topics: Aldehydes; Animals; B-Lymphocytes; Cells, Cultured; Deferoxamine; Disease Models, Animal; Humans; Hy | 2006 |
Cellular iron concentrations directly affect the expression levels of norepinephrine transporter in PC12 cells and rat brain tissue.
Topics: Animals; Brain; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Food, Formul | 2006 |
Iron overload enhances epithelial cell proliferation in endometriotic lesions induced in a murine model.
Topics: Animals; Cell Division; Deferoxamine; Disease Models, Animal; Disease Progression; Endometriosis; Ep | 2006 |
Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis, Ulcerative; Colon; Deferox | 2007 |
A new hippocampal model for examining intracerebral hemorrhage-related neuronal death: effects of deferoxamine on hemoglobin-induced neuronal death.
Topics: Animals; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Hemoglobins; Hippoca | 2007 |
Effects of deferoxamine on blood-brain barrier disruption and VEGF in focal cerebral ischemia.
Topics: Aminoisobutyric Acids; Animals; Blood Pressure; Blood-Brain Barrier; Brain Ischemia; Capillary Perme | 2008 |
Antioxidant treatment prevented late memory impairment in an animal model of sepsis.
Topics: Acetylcysteine; Animals; Antioxidants; Avoidance Learning; Cecum; Deferoxamine; Disease Models, Anim | 2007 |
Clinical evaluation of desferrioxamine (DFO) for removal of thallium ions in rat.
Topics: Animals; Chelating Agents; Chelation Therapy; Deferoxamine; Disease Models, Animal; Iron; Iron Defic | 2007 |
Dysregulation of hepatic iron with aging: implications for heat stress-induced oxidative liver injury.
Topics: Age Factors; Aging; Animals; Deferoxamine; Disease Models, Animal; Ferritins; Heat Stress Disorders; | 2008 |
Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats.
Topics: Animals; Brain Stem; Cerebrovascular Circulation; Deferoxamine; Disease Models, Animal; Electrophore | 2008 |
Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desferrioxamine against hypoxic-ischemic injury in neonatal rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Cobalt; Deferoxamine; Disease Models, Animal; Fe | 2008 |
Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Deferoxamine; Disease Models, Animal; | 2008 |
Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain.
Topics: Animals; Brain; Brain Infarction; Brain Ischemia; Chemokine CXCL12; Cyclooxygenase 2; Deferoxamine; | 2008 |
The effect of desferrioxamine on antigen-induced inflammation in the rat air pouch.
Topics: Air; Animals; Deferoxamine; Disease Models, Animal; Exudates and Transudates; Granulation Tissue; Im | 1984 |
Effect of a specific iron chelating agent on animal models of inflammation.
Topics: Acute Disease; Animals; Brain; Catalysis; Chronic Disease; Deferoxamine; Disease Models, Animal; Fem | 1983 |
Fish as models for hemosiderosis.
Topics: Animals; Biopsy; Deferoxamine; Disease Models, Animal; Fishes; Hemosiderin; Hemosiderosis; Iron; Iro | 1980 |
Experimental siderosis of articular chondrocytes cultured in vitro.
Topics: Animals; Ascorbic Acid; Cartilage, Articular; Cattle; Cells, Cultured; Deferoxamine; Disease Models, | 1981 |
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.
Topics: Animals; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 1995 |
Role of oxygen-derived metabolites in the rat gastric mucosal injury induced by nitric oxide donors.
Topics: Animals; Blood Pressure; Catalase; Deferoxamine; Disease Models, Animal; Drug Overdose; Drug Synergi | 1995 |
Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion.
Topics: Animals; Blood-Retinal Barrier; Cats; Deferoxamine; Disease Models, Animal; Electroretinography; Flu | 1994 |
"Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation".
Topics: Acute Disease; Administration, Inhalation; Aerosols; Animals; Antioxidants; Deferoxamine; Disease Mo | 1994 |
Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Animals; Bronchoalveolar Lavage Fluid; Carboxyh | 1994 |
Conjugated deferoxamine reduces blood-brain barrier disruption in experimental optic neuritis.
Topics: Animals; Blood-Brain Barrier; Capillary Permeability; Deferoxamine; Disease Models, Animal; Encephal | 1994 |
Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine.
Topics: Acute Disease; Anemia, Iron-Deficiency; Animals; Carrageenan; Chronic Disease; Deferoxamine; Disease | 1995 |
Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.
Topics: Acidosis; Adenosine Triphosphate; Animals; Brain Ischemia; Deferoxamine; Disease Models, Animal; Dog | 1995 |
Deferoxamine induces hypotension in experimental gram-negative septicemia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Gram-Negative Bacterial Infections; Hemodynamics; Hyp | 1994 |
Complement activation by the hydroxyl radical during intestinal reperfusion.
Topics: Animals; Chemotactic Factors; Complement Activation; Complement C5a; Deferoxamine; Disease Models, A | 1994 |
The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage.
Topics: Animals; Brain; Deferoxamine; Disease Models, Animal; Female; Guinea Pigs; Lipid Peroxides; Male; So | 1994 |
Desferal attenuates TNF release following hepatic ischemia/reperfusion.
Topics: Alanine Transaminase; Animals; Deferoxamine; Disease Models, Animal; Liver; Liver Diseases; Lung Dis | 1994 |
The role of tubular iron accumulation in the remnant kidney.
Topics: Animals; Creatinine; Deferoxamine; Disease Models, Animal; Electron Probe Microanalysis; Ferric Comp | 1994 |
Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury.
Topics: Animals; Deferoxamine; Disease Models, Animal; Electrocardiography; Female; Free Radicals; Hydroxyl | 1993 |
Antioxidant defenses and its modulation by iron in carrageenan-induced inflammation in rats.
Topics: Animals; Antioxidants; Ascorbic Acid; Carrageenan; Deferoxamine; Disease Models, Animal; Granuloma; | 1993 |
Pulmonary toxicity of deferoxamine in iron-poisoned mice.
Topics: Animals; Atmosphere Exposure Chambers; Bronchoalveolar Lavage Fluid; Deferoxamine; Disease Models, A | 1993 |
Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle.
Topics: Animals; Antioxidants; Calcium; Cell Line; Cell Survival; Chelating Agents; Chromans; Deferoxamine; | 1995 |
Iron complexation with oral deferoxamine in a swine model.
Topics: Administration, Oral; Animals; Antidotes; Deferoxamine; Disease Models, Animal; Dose-Response Relati | 1996 |
Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome.
Topics: Animals; Bleomycin; Deferoxamine; Disease Models, Animal; Iron; Kidney Glomerulus; Kidney Tubules; M | 1996 |
The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
Topics: Aluminum; Animals; Bile; Chelating Agents; Deferoxamine; Disease Models, Animal; Male; Pyridones; Ra | 1996 |
Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage.
Topics: Animals; Carotid Arteries; Deferoxamine; Disease Models, Animal; Female; Ischemic Attack, Transient; | 1996 |
Influence of hydroxypyridones and desferrioxamine on the mobilization of aluminium from tissues of aluminium-loaded rats.
Topics: Aluminum; Animals; Antidotes; Deferoxamine; Disease Models, Animal; Male; Pyridones; Rats; Rats, Wis | 1995 |
Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Deferoxamine; Disease Models, Animal; Electroretinog | 1997 |
[Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
Topics: Animals; Deferoxamine; Disease Models, Animal; Female; Hemosiderosis; Iron; Iron Chelating Agents; M | 1996 |
The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis.
Topics: Acetic Acid; Animals; Calcium Channel Blockers; Catalase; Colitis; Colonic Diseases; Deferoxamine; D | 1997 |
Role of iron and iron chelation therapy in oxygen free radical mediated tissue injury in an ascending mouse model of chronic pyelonephritis.
Topics: Animals; Chelation Therapy; Chronic Disease; Citric Acid; Deferoxamine; Disease Models, Animal; Drug | 1997 |
Topical use of zinc desferrioxamine for corneal alkali injury in a rabbit model.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Burns, Chemical; Cornea; Corneal Injuries; | 1998 |
Application of various antioxidants in the treatment of influenza.
Topics: Allopurinol; Animals; Antioxidants; Deferoxamine; Disease Models, Animal; Influenza A virus; Lethal | 1997 |
The effects of free oxygen radical scavenger and platelet-activating factor antagonist agents in experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Deferoxamine; Disease Models, Animal; Edema; Free Radi | 1999 |
Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species.
Topics: Animals; Chelating Agents; Cyclic N-Oxides; Deferoxamine; Disease Models, Animal; Edetic Acid; Esche | 1999 |
Effects of clinically used antioxidants in experimental pneumococcal meningitis.
Topics: Acetylcysteine; Animals; Antioxidants; Deferoxamine; Disease Models, Animal; Meningitis, Pneumococca | 2000 |
Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat.
Topics: Acute Kidney Injury; Animals; Cell Membrane Permeability; Cell Separation; Cells, Cultured; Chelatin | 2000 |
Starch-deferoxamine conjugate inhibits hepatocyte Ca2+ uptake during hemorrhagic shock and resuscitation.
Topics: Animals; Calcium; Deferoxamine; Disease Models, Animal; Hemodynamics; Hydroxyethyl Starch Derivative | 2000 |
The push-and-pull mechanism to scavenge redox-active transition metals: a novel concept in myocardial protection.
Topics: Analysis of Variance; Animals; Cardioplegic Solutions; Deferoxamine; Disease Models, Animal; Drug Sy | 2001 |
Kupffer cells and neutrophils as paracrine regulators of the heme oxygenase-1 gene in hepatocytes after hemorrhagic shock.
Topics: Acetylcysteine; Animals; Antioxidants; Blood Pressure; Cells, Cultured; Chromans; Clodronic Acid; De | 2001 |
[Relationship between dopamine and iron contents in the brain of parkinsonian rats].
Topics: Animals; Brain; Caudate Nucleus; Deferoxamine; Disease Models, Animal; Dopamine; Female; Iron; Neuro | 2001 |
Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products.
Topics: Animals; Bilirubin; Brain; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; F | 2002 |
The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
Topics: Animals; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Gerbillinae; Iron Chelating Agen | 2002 |
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Topics: Acute Disease; Animals; Blood Pressure; Cebus; Chronic Disease; Deferoxamine; Disease Models, Animal | 2002 |
Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity.
Topics: Animals; Biopsy, Needle; Cisplatin; Deferoxamine; Disease Models, Animal; Dose-Response Relationship | 2002 |
[Study of some agents modifying in vivo distribution of gallium-67 citrate].
Topics: Abscess; Animals; Deferoxamine; Disease Models, Animal; Ferric Compounds; Gallium Radioisotopes; Iro | 1979 |
Deferoxamine effect on selenite-induced cataract formation in rats.
Topics: Animals; Body Weight; Calcium; Cataract; Deferoxamine; Disease Models, Animal; Glutathione; Injectio | 1992 |
Treatment of reperfusion injury in dogs with experimentally induced gastric dilatation-volvulus.
Topics: Animals; Deferoxamine; Dimethyl Sulfoxide; Disease Models, Animal; Dog Diseases; Dogs; Gastric Dilat | 1992 |
Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Topics: Animals; Brain; Deferiprone; Deferoxamine; Disease Models, Animal; Ferrous Compounds; Heart; Hemochr | 1992 |
Yersinia enterocolitica serotype 0:3-induced arthritis in mice: microbiological and histopathological information.
Topics: Animals; Arthritis, Infectious; Bone Marrow; Cartilage, Articular; Deferoxamine; Disease Models, Ani | 1992 |
Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis.
Topics: Acute Disease; Administration, Oral; Allopurinol; Animals; Antioxidants; Catalase; Ceruletide; Choli | 1992 |
Aluminum toxicity.
Topics: Aluminum; Anemia; Animals; Deferoxamine; Dementia; Disease Models, Animal; Humans; Kidney Failure, C | 1991 |
Comparison of the efficacy of mechanistically different antioxidants in the rat hemorrhagic shock model.
Topics: Animals; Antioxidants; Chromans; Deferoxamine; Disease Models, Animal; Ibuprofen; Lipid Peroxidation | 1991 |
A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage.
Topics: Animals; Basilar Artery; Brain; Deferoxamine; Disease Models, Animal; Iron Chelating Agents; Ischemi | 1991 |
Evidence for an early free radical-mediated reperfusion injury in frostbite.
Topics: Allopurinol; Animals; Deferoxamine; Disease Models, Animal; Ear; Free Radicals; Freezing; Frostbite; | 1991 |
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Eflornithine; Female; Pneumonia, Pneumocystis; Random | 1990 |
An ovine model of maternal iron poisoning in pregnancy.
Topics: Animals; Blood Pressure; Body Weight; Deferoxamine; Disease Models, Animal; Female; Ferric Compounds | 1990 |
A model for desferrioxamine-induced retinopathy using the albino rat.
Topics: Animals; Dark Adaptation; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; El | 1990 |
A non-human primate model for the study of oral iron chelators.
Topics: Administration, Oral; Animals; Cebus; Deferoxamine; Dihydropyridines; Disease Models, Animal; Inject | 1989 |
Acute iron poisoning. Rescue with macromolecular chelators.
Topics: Acute Disease; Animals; Deferoxamine; Disease Models, Animal; Iron; Iron Chelating Agents; Male; Mic | 1989 |
Inactivation of creatine phosphokinase by superoxide during reperfusion injury.
Topics: Animals; Catalase; Cattle; Coronary Disease; Creatine Kinase; Deferoxamine; Disease Models, Animal; | 1988 |
The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
Topics: Aluminum; Animals; Bone Diseases; Deferoxamine; Disease Models, Animal; Kidney Failure, Chronic; Mal | 1988 |
Effect of iron chelation on severity of ocular inflammation in an animal model.
Topics: Animals; Anti-Inflammatory Agents; Antigens; Arrestin; Choroiditis; Deferoxamine; Disease Models, An | 1986 |
The post treatment experiment: an operational definition of reperfusion injury.
Topics: Allopurinol; Animals; Creatine Kinase; Deferoxamine; Disease Models, Animal; Heart Arrest; Ischemia; | 1988 |
Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Disease Models, Animal; Glycerol; Hemoglobins; Iron; Kid | 1988 |
Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria.
Topics: 5-Aminolevulinate Synthetase; Animals; Body Weight; Carboxy-Lyases; Chlorobenzenes; Deferoxamine; Di | 1986 |
Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
Topics: Animals; Chelating Agents; Deferoxamine; Disease Models, Animal; Erythrocytes; Hemosiderosis; Hydrox | 1986 |
Involvement of hydrogen peroxide and hydroxyl radical in the 'oxygen paradox': reduction of creatine kinase release by catalase, allopurinol or deferoxamine, but not by superoxide dismutase.
Topics: Allopurinol; Animals; Blood Pressure; Catalase; Coronary Circulation; Coronary Disease; Creatine Kin | 1985 |
Desferrioxamine and Alzheimer's dementia.
Topics: Alzheimer Disease; Animals; Deferoxamine; Disease Models, Animal; Humans; Rabbits | 1985 |
The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
Topics: Administration, Oral; Animals; Ascorbic Acid; Benzoates; Blood Transfusion; Body Weight; Calcium; Ca | 1974 |